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Working in a nursing home with a warm-hearted staff culture, aimed at quality of 
treatment and care, is an inspiring and contagious experience. As a young doctor in 
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Sitting around the lunch table brainstorming clinical cases, research questions, or ideas 
for electronic patient record forms with Kjell, Einar, Marit, Kjellaug, Magne and other 
dear nursing home colleagues in Bergen provided exactly the arena for reflection, 
professional and social exchange that I believe all nursing home doctors need in order 
to blossom.  
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I could not have asked for better supervisors. Sabine, you have both challenged me 
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admire you both. 
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the Kavli Research Centre for Ageing and Dementia for the funding that made this 
project possible. 
Uni research has for the most part of the project period been my employer, clearly 
working to empower researchers in the best way possible. The Research Unit for 
General Practice has provided a productive and positive work environment, with 
exemplary colleagues. I have learnt immensely from our group discussions.  
To my colleagues in Samnanger, both at the office and at the nursing home 
Samnangerheimen, for your flexibility and for being who you are. I have looked 
forward to come to work. 
To my family. You put work in perspective. Edel, your patience with me is beyond 
comprehension. Henry and Alva Marie, you are my inspiration. 
Countless conversations and philosophical musings with my mother and father have 
formed me. Crucially, in the midst of analysis in the spring of 2015, my father became 
ill with bile duct cancer, and lived for a little more than two months after diagnosis. He 
lived in Spain, his birth country, and enjoyed morning walks to the local cafeteria, 
where he’d have a breakfast of croissant and coffee in the warm shadow of orange 
trees, and the familiar sounds of his mother tongue. However, he had little family to 
care for him there. Home care services, a hospice or a decent nursing home were 
lacking. And so, three weeks before he died, he expressed in despair from his hospital 
bed a wish to come to Norway. A move I had insisted he make for several weeks, to 
ensure dignified care for him in his last days, close to his remaining family. He spent a 
precious last two weeks in a nursing home in Bergen, and I witnessed and shared his 
last days and hours and breaths of life. My own vulnerability bare, and the 
impermanence of existence so palpably reminded, the concept of existential 
vulnerability felt very real when suggested by Margrethe.  




Nursing homes are the main arena for end-of-life (EOL) care in Norway. Patients, 
their informal caregivers and academics alike have called for doctors more involved in 
EOL care, but the nursing home doctor’s role has been given relatively little attention 
in research.  
This thesis explores the doctor’s work with EOL care in nursing homes from the 
perspectives of EOL prescription changes (paper I); the effectiveness and safety of 
palliative prescriptions (paper II); and from nursing home doctors’ own experiences 
and how their existential vulnerability impacts on their work (paper III).  
Paper I 
Methods. A historical cohort study, set in three urban nursing homes in Norway, 
between January 2008 and February 2013. Drug prescriptions, diagnoses, and 
demographic data were collected from electronic patient records.  
Results. 524 patients were included. On the day of death, almost all patients had active 
prescriptions; around three out of four patients were prescribed palliative drugs. 
Palliative drugs were associated with nursing home, length of stay >16 months, age, 
and a diagnosis of cancer. Initiations of palliative drugs and withdrawals of 
curative/preventive drugs most commonly took place on the day of death. 
Paper II  
Methods. A systematic search of the literature published before December 2016, 
including studies on safety or effectiveness of drug therapy in dying adults with at 
least one outcome on symptom control, adverse effects, or survival.  
Results. Of 5940 unique titles identified, 12 studies met the inclusion criteria. Five 
studies assessed anticholinergics for death rattle, providing no evidence that 
scopolamine hydrobromide or atropine were superior to placebo. Five studies 
examined drugs for dyspnea, anxiety, or terminal restlessness, providing some 
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evidence supporting the use of morphine and midazolam. Two studies examined 
opioids for pain, providing some support for morphine, diamorphine and fentanyl. 
Eight studies included safety outcomes, revealing no important differences in adverse 
effects between the interventions, and no evidence for midazolam shortening survival. 
Paper III 
Methods. A qualitative study based on three focus group interviews with purposive 
samples of 17 nursing home doctors. The interviews were audio-recorded, transcribed, 
and analyzed with systematic text condensation (STC). 
Results. Nursing home doctors interviewed in paper III experienced having to balance 
treatment compromises in order to assist patients’ and families’ preparation for death, 
with their sense of professional conduct. This was an arduous process demanding 
patience and consideration. Existential vulnerability also manifested as powerlessness 
mastering issues of life and death and families’ expectations. Personal commitment 
was balanced with protective disengagement on the patient’s deathbed, triggering both 
feelings of wonder and guilt.  
Conclusion  
Palliative drug therapy and drug therapy changes are common for nursing home 
patients on the last day of life. Improvements in end-of-life care in nursing homes 
imply addressing prognostication and an earlier response to palliative needs. 
There is a lack of evidence concerning the effectiveness and safety of palliative drug 
treatment in dying patients, and the reviewed evidence provides limited guidance for 
clinicians. Anticholinergic agents are not supported for the treatment of death rattle. 
Existential vulnerability is experienced by nursing home doctors as a burden of 
powerlessness and guilt in difficult treatment compromises and in the need for 
protective disengagement, but also as a resource in communication and professional 
coping.  
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Sammendrag på norsk 
Sykehjem er den fremste arena for terminalomsorg i Norge. Legens økte involvering i 
terminalomsorgen er etterspurt av pasientene, deres omsorgspersoner, og fagmiljøet, 
men har fått relativt liten oppmerksomhet i forskning.  
Denne avhandlingen utforsker sykehjemslegens arbeid i terminalomsorgen, fra tre 
forskjellige perspektiv: legemiddelendringer på sykehjem ved livets slutt (artikkel I), 
evidens for nytte og sikkerhet ved lindrende legemidler ved livets slutt (artikkel II), og 
sykehjemslegens egne erfaringer, og hvordan deres eksistensielle sårbarhet påvirker 
deres arbeid.  
Artikkel I 
Metode. En historisk kohort studie, gjennomført ved tre by-sykehjem i Norge, i 
perioden januar 2008 til februar 2013. Legemiddelforskrivninger, diagnoser, og 
demografiske data ble innsamlet fra elektronisk pasientjournal.  
Resultat. 524 pasienter ble inkludert. På dødsdagen hadde nær alle pasienter aktive 
legemiddel-forskrivninger; omkring 3 av 4 sto på lindrende legemidler. Lindrende 
legemidler var forbundet med sykehjem, oppholdsvarighet over 16 måneder, alder, og 
kreftdiagnose. Flest endringer av lindrende legemidler og seponeringer av 
kurativ/preventive legemidler skjedde på dødsdagen.  
Artikkel II 
Metode. Systematisk litteratursøk av publikasjoner frem til desember 2016 på 
effektivitet og sikkerhet av legemiddelbehandling av døende voksne pasienter med 
minst ett utfallsmål innen symptomkontroll, bivirkning eller overlevelse.  
Resultater. Av 5940 unike titler identifisert, møtte 12 inklusjonskriteriene. Fem studier 
omhandlet antikolinerge legemidler for dødsralling, og viste ingen evidens for at 
skopolamin hydrobromid eller atropin var bedre enn placebo. Fem studier undersøkte 
legemiddelbehandling av tungpust, angst, og terminal rastløshet/uro, og viste noe 
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støtte for bruken av morfin og midazolam. To studier undersøkte opiater for smerte, og 
viste noe støtte for morfin, heroin, og fentanyl. Åtte studier undersøkte 
legemiddelsikkerhet, og viste ingen nevneverdige forskjeller i bivirkninger mellom 
intervensjoner, og uendret overlevelse ved bruk av midazolam.    
Artikkel III 
Metode. En kvalitativ studie basert på tre fokusgruppeintervju med strategisk utvalg av 
17 sykehjemsleger. Intervjuene ble tatt opp, transkribert, og analysert med systematisk 
tekstkondensering.  
Resultater. Sykehjemslegene erfarte å balansere behandlingskompromisser for 
behjelpe pasient og pårørendes forberedelse til døden, med deres egen profesjonalitet. 
Dette var en prosess som krevde tålmodighet og omtanke. Eksistensiell sårbarhet ble 
også uttrykt som maktesløshet i å mestre liv og død, og pårørendes forventninger til 
legen. På pasientens dødsleie ble personlig nærhet avveid mot beskyttende distanse, og 
kunne utløse følelser både av skyld og ærefrykt. 
Konklusjon 
Lindrende legemiddelbehandling og endringer i legemidler er vanlige ved livets slutt 
for sykehjemspasienter. Forbedringer i terminalomsorgen innebærer bedre 
prognostisering av døden, og en tidligere respons på palliative behov.  
Det er mangel på evidens for effekt og sikkerhet av lindrende legemiddelbehandling 
av dødende pasienter, og gjennomgått evidens alene gir lite veiledning for klinikere. 
Antikolinerge medikamenter støttes ikke for behandling av dødsralling. 
Eksistensiell sårbarhet erfares av sykehjemsleger både som en byrde av maktesløshet 
og skyldfølelse ved vanskelige behandlingskompromiss, og i behovet for beskyttende 
distanse fra pasientsituasjoner, men også som en ressurs i kommunikasjon og 
profesjonell mestring.  
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1.1 The concepts of palliative care, end of life, and dying 
The World Health Organization (WHO) defined palliative care in 2002 as “an 
approach that improves the quality of life of patients and their families facing the 
problem associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and treatment of 
pain and other problems, physical, psychosocial and spiritual.”(1) Closely resembling 
the WHO definition of 1990, palliative care is defined by the European Association of 
Palliative Care as “... the active, total care of the patient whose disease is not 
responsive to curative treatment.” (2)  
In contrast to these standardizations of the palliative care concept, various and 
inconsistently defined terms are used in the palliative care literature to refer to the 
dying stages of illness or the last period of life. Several reasons have been proposed to 
explain this, such as the multidisciplinary nature of palliative care, the common 
euphemisms surrounding death and dying, and regional variations in the structures and 
processes of palliative care programs. (3) 
Confusing inconsistencies surround in particular the time period meant in concepts 
such as ”end of life” (EOL), ”terminal care”, ”dying” and ”actively dying”, referring 
to everything from hours to several years. (4) Speaking in specific time frames such as 
months, weeks, or days has therefore been recommended when communicating with 
patients about their prognosis. (5, 6) For research purposes, two different approaches 
may be used in defining the dying stages, depending on whether the term is defined 
prospectively or retrospectively: 1) a survival prognosis based on the clinical 
judgement of irreversible decline of physiological function before death, or 2) 
retrospectively ascertained time from study observation to death. 
A 2014 systematic review of the definitions of these terms used in the research 
literature, textbooks, dictionaries and palliative organization websites, found that the 
terms “end of life”, “terminally ill”, and “terminal care” share a similar meaning: 
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progressive life-limiting disease with a prognosis of months or less. (4) The same 
review found that the term ”actively dying” specifically relates to the last hours and 
days of life but is seldom used in the literature.  
EOL care is generally defined as palliative care provided at the EOL, while palliative 
care extends all the way from the point of diagnosis of a life-threatening condition. (7) 
EOL care is therefore more appropriate where care concerns an expected end to life 
from old age such as commonly is the case in nursing homes. EOL and EOL care may 
be used in a wide definition of the last two years, and a narrow definition of the last 
few hours or days of life. (2) Although this distinction may not always be needed, this 
thesis generally adheres to the narrow meaning of the word.  
1.2 EOL care in Norwegian nursing homes 
Of the approximately 40,000 people that died in 2015, 48 % died in a nursing home, 
whereas 31% died in a hospital and 14% at home. (8) This makes nursing homes the 
most common setting for EOL care in Norway.  
Care at long-term care (LTC) wards in nursing homes implies EOL care in the wide 
sense - patients deceased here reside on average only two years before dying. And 
while the older population in Norway is generally becoming healthier, nursing homes 
are home to the very frailest, and increasingly so. (9, 10) Nursing home patients to a 
greater extent than ever have complex health problems and functional impairment, 
requiring more medical and nursing services. Nursing home patients in Norway are on 
average 84.1 years old. Around 70% are women, who are on average are 5 years older 
than men. Around 80% are in long-term stays, 80% have significant need for 
assistance, (10) and 80% have some degree of dementia. (11)  
While some nursing homes have dedicated palliative beds, specialized palliative 
services are generally offered by multidisciplinary teams in palliative care units and 
outpatient clinics in hospitals. By March 2017, there were 40 specialized palliative 
care units in Norway, 42 municipal palliative care units (nursing homes with more 
than four dedicated palliative beds), and 99 municipal nursing homes with (less than 
 15 
four) dedicated palliative beds. (12) 
In terms of resources in an international perspective, Norway gives high priority to 
elderly care and LTC facilities, with relative national health expenditures on LTC 
facilities comparable mainly to the Netherlands, Switzerland, Belgium, Denmark, and 
Sweden. (13)  
All health care personnel treating dying patients, both in municipally-governed 
primary care such as nursing homes and home care, and in state-governed secondary 
and tertiary care, are expected to offer basic palliative care services to any patients in 
need, implying satisfactory symptom control and care at the EOL according to the 
WHO principles of palliative care, (1) as well as knowledge of when to refer the 
patient to specialized services, and preferably hosting an advanced practice registered 
nurse (ressursykepleier). (14) Most nursing home staff have professional or vocational 
training such as registered nurses, nursing assistants, physiotherapists and occupational 
therapists.  
Nursing home doctors in Norway are a blend of general practitioners providing a part-
time service and, increasingly, dedicated nursing home doctors commonly working at 
larger nursing homes. Since 2012, an “Area of Competence” (Kompetanseområde) for 
Elderly and Nursing Home Medicine has been available for certification, building 
upon the specialties of general practice, internal medicine, geriatrics, neurology, or 
physical and rehabilitation medicine. (15) Similarly, there is no specialty of palliative 
medicine in Norway, but since 2011, an Area of Competence as a training program 
and certification building on any other clinical specialty. (16) 
Nursing home doctors in Norway and the Netherlands find inadequate staffing levels, 
lack of competence, time, and interest as important barriers to quality EOL care. (17) 
Nevertheless, newly qualified doctors in Norway find considerable opportunity in 
nursing homes for training in patient and family dialogues, complex decision-making 
and interdisciplinary work. (18) 
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1.3 Working for a “good death” – the tasks of the nursing home doctor  
According to nurses, a dignified death in LTC facilities means treating patients with 
respect, helping them prepare for the EOL, promoting shared decision-making, and 
providing high-quality care. (19) According to relatives of LTC residents with 
dementia, patients' optimistic attitude, physical and psychological distress, and facility 
characteristics are associated with dying peacefully, (20, 21) and quality of life is 
associated with age, functional status, dementia severity, pain, psychiatric disorders, 
pulmonary diseases and neuropsychiatric symptoms. (22) 
Efforts to define a good death point to some key tasks in EOL care for the nursing 
home staff: symptom management, communication and knowledge of preferences for 
care, a focus on quality of life, and taking care of the family. (23) The nursing home 
doctor has a central role in these tasks, the domains of which are addressed in the 
following sections.  
Distress relief  
Dying patients in nursing homes often have physical distress and need for 
symptomatic relief. (24) Common symptoms across care settings in the last two weeks 
of life death are dyspnea, weakness, respiratory secretions and pain. (25) A large 
Swedish nursing home register study found pain in the last week of life in almost 60% 
of patients, followed in order of prevalence by death rattle, anxiety, confusion, 
dyspnea (breathlessness) and nausea. (26) A longitudinal study in Norwegian nursing 
homes found that fatigue, drowsiness, and poor appetite were the most common 
symptoms on the day of death. (27) In another study on LTC patients in their last 8 
hours of life, dyspnea, pain and noisy breathing were most common. (28) 
For the dying phase, palliative care guidelines consistently recommend parenteral 
pharmacological symptom relief options such as opioids for pain or dyspnea, 
benzodiazepines for dyspnea, anxiety or delirium, antipsychotics for terminal delirium 
and agitation, and antimuscarinic anticholinergics for respiratory secretions. (14, 29-
37) 
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The 2015 NICE guidelines on Care of dying adults in the last days of life (30) 
reviewed comparative studies on symptomatic drug treatment in the last 14 days of 
life. The NICE guidelines report one study on drug treatment of pain, three studies on 
breathlessness, three studies on nausea, and eight studies on respiratory tract 
secretions. However, for the treatment of other common symptoms in dying persons, 
such as anxiety, delirium or agitation no evidence is provided in the NICE guidelines 
nor in two earlier Cochrane reviews on a broader palliative care population. (38, 39)  
As a precondition for responding to the need for symptomatic relief and the changing 
priorities of care as the patient approaches death, staff must also have a concept of 
remaining life-expectancy, and the ability to identify that the patient is actively dying. 
(40) This issue will be further addressed in the discussion section.  
Deprescribing  
Deprescribing is “the process of withdrawal of an inappropriate medication, 
supervised by a health care professional with the goal of managing polypharmacy and 
improving outcomes”, (41) and involves identifying and balancing existing or 
potential harms to benefits within the context of an individual patient’s life 
expectancy, care goals, level of functioning, values and preferences. (42) As death 
approaches, these goals and balances will change: preventive drugs will lose 
relevance, and palliative drugs gain in kind. (43-45)  
Nursing home patients are commonly prescribed many drugs (polypharmacy) for 
numerous illnesses (multimorbidity) and ailments. Patients in Norwegian nursing 
homes take an average of six to seven different daily regular medications. (46-48). 
Polypharmacy is associated with drug-related problems such as adverse drug reactions, 
drug-drug interactions, functional decline, cognitive impairment and falls. (49-51) In 
nursing home patients with advanced dementia, it is also associated with increased 
mortality,(52) and hospital readmissions. (53-56)  
Few rigorous studies have been conducted on deprescribing in the context of life-
limiting illness and dying patients, but show that patients in all care settings continue 
to receive medications that are not prescribed for symptomatic treatment, that limited 
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evidence exists on the safety and efficacy of drugs, and that prescribing guidelines 
lack. (44, 57)  Despite a growing interest in research on deprescribing in nursing 
homes, (58) nursing home patients are particularly underrepresented in clinical trials, 
further hindering the production of evidence to support guidelines in this population. 
(59, 60)  
Advance care planning 
Since what represents a good death differs between individuals, shared decision-
making regarding treatment, recognizing the differences in values and preferences of 
patients and their families is needed. (61) Such conversations with patient and family 
adjusting aims of treatment and care are referred to as Advance care planning (ACP).  
Rather than necessarily resulting in written treatment directives, sometimes referred to 
as ”advance directives” or ”physician/medical treatment orders” (see below), ACP can 
be regarded as a process supporting the shared decision-making between doctor, 
patient and family. (62) In a recent consensus statement, ACP is defined as follows: 
”Advance care planning is a process that supports adults at any age or stage of health 
in understanding and sharing their personal values, life goals, and preferences 
regarding future medical care. The goal of advance care planning is to help ensure that 
people receive medical care that is consistent with their values, goals and preferences 
during serious and chronic illness.” (25) While ACP may be initiated in various ways, 
(63-66) the doctor in charge of treatment must take the main responsibility and 
initiative. In Norway, family and doctor participate in ACP conversations but, likely 
due to lack of cognitive ability, only sometimes the patient. (66-68) ACP is more 
likely to be done in nursing homes with good availability of doctors. (66). 
Treatment orders / advance directives 
Do-not-resuscitate orders, physician treatment orders for life-sustaining treatments, 
palliative care consultations, and multi-strategy interventions can help reduce hospital 
transfers from LTC facilities. (69-74) However, formalized physician treatment orders 
may be difficult to understand, interpret and explain, and are often based on limited 
discussions between doctors, patient and family. (72, 75, 76) Difficulties predicting the 
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impact of an illness and its treatment on future subjective well-being are likely to 
hinder such directives. (75, 77, 78) Complex ACP interventions may be more effective 
in meeting patients' preferences than such written orders alone. (79) Both the ACP 
process at large and treatment orders in particular, nevertheless represent a shift in 
treatment goals from a life-extending curative/preventive treatment perspective, to a 
palliative care approach focusing on the immediate quality of life. Palliative care 
approaches in nursing homes have shown to improve care, reduce hospitalizations and 
costs, and improve family members' perception of care. (80-84)  
Relating to the “extended patient” of nearest family 
Considering the value of relatives in aiding proxy assessments, in supporting the 
patient, in being important to the patient, but also themselves suffering from the 
patient’s deterioration and dying, (85-88) the nursing homes doctor and staff must not 
only treat the patient, but the ”extended patient” or ”unit of care” that extends to the 
closest family and friends. (89) The majority of nursing home patients and relatives in 
Norway appreciate talking about EOL care, and want to be involved in decision-
making. (67) Better communication with both patient and family members is 
associated with fewer in-hospital deaths and transfers to hospice, (90) improved 
patient comfort, (91) and reduced family stress. (92) Proxy assessors, including both 
relatives and professional carers, provide an indispensable insight into the nursing 
home patient perspective when he or she is too ill or cognitively impaired to answer 
for him-/herself. However, the views of patients and relatives may differ. Proxies are 
more likely to agree with patient responses on concrete, observable symptoms, patient 
functioning and service provision than on more subjective symptoms and experiences, 
leading for example to an overestimation of pain, and attenuation of self-reports 
toward moderate scores. (23, 93) While patients and relatives also differ in views on 
decision-making, patients trust relatives and staff to make important decisions for 
them. (94) 
Unnecessary relocations 
As part of decision-making regarding potentially burdensome life-prolonging 
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treatment, another important goal of care and task for the doctor is to avoid 
unnecessary transfers and relocations. (95) Hospital transfers for palliative care benefit 
the nursing home patient only if care is insufficient at the nursing home. (96) Care 
transitions or relocations between nursing home and hospital or emergency department 
are common, and represent a significant burden to the patient and relatives at the EOL, 
in particular in patients with dementia. (71, 97-99) In Norway, large differences in 
admission rates between institutions in the same municipality have been shown, 
pointing to a potential for reduction of unnecessary admissions. (100-102) Infections, 
fractures and cardiovascular disease are the most common reasons for admission. (100, 
101)  
In summary, the nursing home doctor must consider prognosis and engage in ACP 
dialogue with patient and family both as part of, and prerequisite to, treatment 
decision-making. How nursing home doctors relate to and execute these tasks, 
however, and the doctor’s own perceptions of role and challenges as part of the EOL 
care team, is not answered by a simple list of tasks, and deserves investigation. This 
thesis investigates prescription changes in dying nursing home patients, (paper I) 
examines the evidence base for palliative drug prescriptions in the dying, (paper II) 
and explores nursing home doctors’ experiences of working with dying patients. 
(paper III) 
1.4 The nursing home doctors’ experiences of EOL care 
Palliative care is no doubt a team effort. (1) The perspectives of family members, care 
providers, and experts alike are integrated in models of care. (23) As one can expect, 
however, care team members´ perceptions regarding EOL care in the LTC setting 
differ. (61, 103) For example, nursing aides have been found to perceive more patient 
pain at the EOL compared to doctors or nurses, and doctors' perceptions of emotional 
support provided to families are lower than those of aides or nurses. (104) Doctors’ 
experiences naturally also differ from family members’. Doctors perceive higher-
quality aspects of nursing care and outcome, better consensus between staff and family 
on treatment, and a more peaceful death than family members. (105) While doctors, 
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nurses and relatives agree on many aspects of EOL decision-making for nursing home 
patients with dementia, relatives attach more importance to advance directives than 
doctors, and have more permissive attitudes towards hastening death. (106) 
Nursing home patients and their relatives clearly want doctors more involved in EOL 
care and ACP discussions (67, 107-109) Family caregivers want face-to-face meetings 
with doctors about health changes, especially in the actively dying. (110) A stronger 
involvement by nursing homes in palliative care has also been called for by academics. 
(111)  
We should expect time spent with the patient to be correlated with personal and 
emotional involvement, and burden of care. Closest to the patient is family, whose 
experiences and burden have been extensively studied. (112-114) Next, nursing staff 
in LTC will typically spend time with fewer patients than doctors, more time per 
patient, and get to know patients in an intimate setting of personal hygiene and daily 
informal conversation to which the doctor has less access. Perhaps therefore, relative 
to the patient, family and nursing staff perspectives, doctor’s experiences with dying 
nursing home patients have been infrequently investigated. Nevertheless, doctors, far 
from stereotypes of objective and aloof clinicians, may still have close meetings with 
patients, and will have psychological responses to their experiences. In order to better 
understand doctors’ important and sought-after contribution to improving EOL care in 
nursing homes, their voices must be heard.  
Of note, Bern-Klug has interviewed nursing home doctors, finding that they consider 
consensus with the patient, family and other staff about the patient’s status and an 
appropriate care plan to be important aspects of good EOL care. (115) Doctors also 
feel their work provides positive relationships, meaningful patient care, and autonomy; 
but difficult staff turnover, expectations, and administrative issues. (116) Other 
research has primarily focused on nursing home doctor’s experiences with ACP (63, 
65, 68, 106, 117, 118), and euthanasia (76, 119-121), the latter subject being outside 
the scope of this thesis. 
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This thesis promotes the nursing home doctor’s perspective of role in EOL care not 
only indirectly by a focus on drug treatment at the EOL (paper I and II), for which the 
doctor is primarily responsible, but directly by exploring nursing home doctor’s own 
experiences (paper III). 
1.5 The doctor’s existential concerns 
The existential perspective is a natural one to bring up in the setting of nursing homes, 
where existence is threatened by illness, loss of function, and the prospect of death. 
The existential perspective is closely related to the spiritual perspective but need not 
be religious, and while existential concerns may be discussed in psychological terms, 
they need not amount to psychiatric disorders like depression. (122)  
Normally, existential concerns in palliative care literature revolves around the patient, 
the protagonist of illness and death, searching for purpose and meaning to suffering 
(122, 123) Common themes of concern to terminally ill patients may be dependency, 
meaninglessness, hopelessness, being a burden on others, loss of social role, and 
feeling emotionally irrelevant. (124) Existential concerns and distress are common in 
nursing home patients at the EOL. (125) Little, however, is known about professional 
palliative care providers’ existential concerns supporting patients at the EOL. (126, 
127)  
The existential perspective has been explored by existentialist philosophers like Søren 
Kierkegaard, Victor Frankl, Jean Paul Sartre, Martin Heidegger, and in psychiatry 
famously by Irvin Yalom. David W. Kissane, a psychiatrist and palliative care 
researcher, is best known for his model of family therapy in palliative care, (128) and 
his work on demoralization. (129) Building on the work of Yalom (130), Kissane 
suggests eight types of existential challenges for patients with advanced illness: 1) 
death anxiety, 2) loss and change, 3) freedom with choice, 4) dignity of the self, 5) 
fundamental aloneness, 6) altered quality of relationships, 7) meaning, and 8) mystery. 
(131) To each of these, he offers a suggestion to doctors on how to facilitate adaptive 
responses.  
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Kissane suggests his typology of existential suffering to aid its recognition and 
management in patients. In this thesis, I show how Kissane’s typology of existential 
suffering might also be useful in order to understand the challenges of doctors and 
other staff working in EOL care. However, the doctor’s professional role is defined as 
a contrast to the patient role, thereby potentially also alienating itself from the 
vulnerability of its counterpart. Such an opposition may have consequences for the 
experiences and expressions of existential distress in doctors, their adaptive responses 
and facilitation strategies.  
Arne Johan Vetlesen is a Norwegian philosopher of ethics and social philosophy. 
Vetlesen’s existential approach to the clinical encounter opens for potential strengths 
of the doctor’s own vulnerability to existential suffering. Acknowledging vulnerability 
as a basic element of humanity common to both patient and doctor, he argues, is a 
precondition for accessing the patient’s perspective. (132) Instead of simply being a 
weakness, the doctor’s vulnerability may be valuable to successful patient 
communication, as has also been shown in general practice. (133) Doctors' own 
existential vulnerability facing matters of life and death has been underestimated, 
(134) and it is unclear how such vulnerability should be viewed as part of a 
professional identity. These issues are explored in the context of the nursing home 




The overarching aim of this thesis is to elucidate the doctor’s role in end-of-life care in 
nursing homes, with a particular focus on drug prescriptions and the impact of 
existential vulnerability. The three studies conducted for its purpose had the following 
specific aims: 
 
I. To describe what drugs doctors prescribe to and discontinue for patients near the end 
of life in three Norwegian nursing homes, and identify predictors of a clearly defined 
palliative drug therapy in the last days of life. 
 
II. To systematically review and assess the published literature on the effectiveness 
and safety of drug therapy for distress relief in the last days of life of adult patients. 
 
III. To explore the experiences of doctors working with dying nursing home patients 
and their families, focusing on the existential vulnerability of the doctors. 





This thesis is based on three studies with three different designs; two empirical studies 
and a systematic literature review. Paper I was a historical cohort study, Paper II was a 
systematic literature review, and Paper III was a focus group study.  
3.1 Paper I – Cohort study 
To investigate drug treatment for nursing home patients in the last few days of life, we 
collected drug prescriptions and other routinely registered data from the electronic 
patient records (EPRs).  
Study population and data collection 
We selected three urban nursing homes in Bergen on the basis of using an EPR system 
(GBD) optimized for data extraction, designed with research and quality improvement 
in mind, most importantly by having structured data input. (135) GBD was introduced 
in one nursing home in 2007, and not until later in all three included nursing homes. 
The system is from 2016 distributed to all nursing homes in Bergen. We had a close 
dialogue with the GBD software developer to ensure appropriate extraction of data. 
We also cooperated with representatives from the municipal IT department, who 
provided administrative data on admission and death dates from a separate data source. 
These were the only data not collected from GBD. Many variables were available for 
extraction from GBD, and for these I had to assess their relevance to our study aim, 
data completeness, and roughly assess the face validity and reliability of clinical data 
before deciding whether extraction and further analysis were worthwhile.  
We included all 524 patients admitted from January 2008 and deceased before 
February 2013, and collected demographical data (age, gender, date of nursing home 
admission and death, long- or short term stay); diagnoses (ICD-10);(136) and 
medications (generic name, Anatomical Therapeutic Chemical (ATC) code,(137) drug 
formulation, regular or as-needed schedule, indication, dates of initiation, alteration or 
discontinuation). We cross-checked dates of admission, discharge and death with data 
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from the patient administrative system. Given medication was, at the time of the study, 
still documented on paper, and was not collected as it would have been considerably 
more time-consuming to collect and prepare for analysis.  
Definition of palliative end of life versus curative/preventive drug therapy 
Drug prescriptions were analyzed from the perspective of assumed palliative versus 
curative/preventive purpose in the dying population. This was approximated on the 
basis of indication, drug, and formulation as outlined in Table 1. The patient in this 
phase will at some point be unable to take oral medications, and require a parenteral 
alternative. Since the patient’s condition and symptomatic relief needs may change 
abruptly, the patient will also require pro re nata (PRN) / as-needed / anticipatory 
prescriptions. However, both regular and as-needed prescriptions may be palliative in 
intention, and therefore we did not restrict the definition to as-needed prescriptions. 
All included nursing homes used the care pathway for dying patients formerly known 
as Liverpool Care Pathway, which is why this was included as a key word for dying in 
the prescription indication text. 
Table 1. Definition of drug therapy 
 




1) Any drug prescription with an explicit EOL care indication 
key word was included: palliative, terminal, death, death rattle, 
Liverpool Care Pathway, or EOL  
2) Any prescriptions of specifically recommended injectable 
palliative EOL drugs for use in Norwegian nursing homes, 
(138, 139) regardless of missing EOL key words in the 
indication text 
 
Any medication for 
regular use without 





User rates were established for drugs according to the above categories. Predictors of 
palliative EOL drug therapy were explored by χ2-test, and subsequently by binary 
logistic regression analysis; dependent variable: palliative EOL drug therapy; 
independent variables: age, gender, length of stay, nursing home, diagnosis of cancer. 
All variables except age were analyzed as categorical. Significance was determined at 
a level of 5%. IBM SPSS Statistics 20 (SPSS Inc., Chicago, Ill., USA) was used for 
statistical analyses. 
 
3.2 Paper II – Systematic literature review 
To investigate the evidence for the effectiveness and safety of palliative drug therapy 
in the last days of life, we performed a systematic literature review. We registered the 
study in the PROSPERO database of systematic reviews prior to start, (140) 
(CRD42016029236) to avoid overlapping reviews and reduce the opportunity for 
selective reporting deviating from the planned protocol, known as reporting bias. Here, 
no other similar systematic review was documented. I came across an appendix to a 
draft version of the NICE guidelines of the care of dying adults with search strategy in 
July 2015, from which we adapted the search string to identify the dying population. 
The first date of literature search in our review was in November 2015, a month before 
the NICE guidelines were finally published. At this point the research group did not 
suspect that the NICE guidelines would include similar systematic reviews. We 
reported the study in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines. (141) 
Search strategy, study selection and data extraction  
With the assistance of a university librarian we searched the following databases (final 
search date December 21st 2016): PubMed/MEDLINE, Embase, CINAHL, PsycINFO, 
Cochrane, ClinicalTrials.gov, and SveMed+. We also hand-searched the reference lists 
of all included articles and relevant literature reviews. After removal of all duplicates, 
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studies were evaluated in a stepwise procedure for inclusion in the review (Figure 1), 
based on the inclusion criteria (Table 2). 
 
Table 2. Inclusion/exclusion criteria and outcomes of interest (PICOS) 
P - population Adults (≥18 years) in their last two weeks of life or clinically 
considered dying, in any clinical setting and diagnosis 
I - interventions Palliative drug therapy 
C - comparators Any, where available 
O - outcomes Primary: symptom or symptom control measures regarding pain, 
breathlessness, anxiety, and nausea; number or degree of adverse 
effects; and mortality or survival.  
Secondary: level of consciousness, functional level, quality of 
life, and quality of care. 
S – study designs Experimental or quasi-experimental designs (clinical trial, cohort, 
or case-control) 
 
Two authors (Kristian Jansen and Lisa Pont) performed title and abstract screening. 
Full-text assessments and data extraction were done in author pairs. We extracted data 
on the 12 articles finally included using the McMaster Critical Review Form for 
quantitative studies, (142) adding information on health care setting, time before death 
studied, diagnostic category, drug category, and drug administration route.  
Quality assessment 
We assessed the quality of the 12 finally included studies in author pairs, using the 
Effective Public Health Practice Project (EPHPP) Quality assessment tool for 
quantitative studies, (143) chosen for its applicability across various quantitative study 
designs. Studies were rated weak, moderate or strong on the following six 
components: selection bias, study design, confounders, blinding, data collection, and 
withdrawal. This gave a global rating for each study as follows: weak (two or more 
component weak ratings), moderate (one weak rating), or strong (no weak ratings).  
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3.3 Paper III – Focus group study 
 
To study the experiences of doctors working with dying nursing home patients and 
their families, we used focus group interviews. This design is suited to explore shared 
experiences in groups of participants. (144, 145) We conducted three focus group 
interviews, each including five to six nursing home doctors, from two Norwegian 
municipalities.  
Recruitment 
I recruited participants to the first focus group directly by email to the nursing home 
doctors, after having received the contact information from senior consultants in the 
municipality. In further recruitment this approach did not prove fruitful, and instead I 
approached local groups of nursing home doctors meeting for Continuing Medical 
Education purposes.  
Participants 
Participants were a purposive sample of 17 nursing home doctors, aiming for variation 
in gender (10 women, 7 men), age (33 - 65 years), clinical experience (3 - 29 years), 
part-time or full-time engagement (14 versus 3), and clinical specialty background (3 
doctors were specialists in general practice, 3 hospital specialists, the remainder had 
no specialty background). I knew several participants in the first and second focus 
groups from earlier work as a nursing home doctor in the same municipality.  
Interviews 
In all three focus groups, I served as moderator while the last author served as 
secretary. To start off the conversation, in the first interview we asked participants to 
share a story of a dying nursing home patient that they had found particularly 
challenging. After the first interview, in an attempt to facilitate stories of vulnerability 
or challenges while also allowing for stories of success, participants were instead 
invited to share an experience that had made a profound impression on them. A brief 
interview guide was used (Table 3). Interviews lasted 90 minutes, and were taped and 
transcribed verbatim.  
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Table 3. Brief interview guide.  
 
Point of departure: 
Now I would like for us all to do the following exercise, of holding in our minds the 
image, story or situation of, a dying patient that made a profound impression on us, 
be it in a good way or a bad way. Take a moment to do this. As we speak together 
now, try to return to this patient. Could you please share your experience? How was 
it like? 
Auxiliary questions:  
- How did you experience the assessment of prognostication in the dying? Who 
was the first to understand that the patient is dying, and who was the first to 
point it out? How was it communicated? What clues do you use to assess the 
patient as dying?  
- How were patient, family, staff and you yourself prepared for the death of the 
patient? 
- How does treatment of dying patients differ, if at all, between diagnostic 
groups (dementia, cancer, heart failure)? 
- What did you find particularly challenging? What made it so? 
 
Analysis 
All authors participated in the analytical process following the steps according to 
Systematic Text Condensation (Fig. 2). (146) First, we read the transcripts for an 
overall impression, identifying preliminary themes. Second, all authors independently 
identified units of meaning and coded these, representing different aspects of 
challenging experiences in EOL care and how these were dealt with. Third, we 
abstracted the content of the code groups and subgroups into condensates, each 
illustrated by a quotation. Fourth, we developed generalized descriptions of 
experiences with dying patients associated with existential vulnerability in an iterative 
process. In reaching the final categories, theoretical perspectives from Kissane’s 
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exposition of existential challenges for patients with advanced illness (131) and 
Vetlesen’s emphasis on the vulnerability of the doctor (132, 147) assisted the 
interpretation and focus on existential vulnerability. 
 
Figure 2. Analytic process – systematic text condensation (Modified with permission 
from: Malterud K. Kvalitative metoder i medisinsk forskning. [Qualitative methods in 




3.4 Ethics and approval 
Paper I: We met with representatives from the municipality of Bergen as well as the 
directors of the three included municipal nursing homes before data collection, 
achieving approval for participation in the project.   
The Western Regional Committee for Medical and Health Research Ethics (REC west) 
(2012/1748) and the Norwegian Social Science Data Services (NSD) (#30691) 
approved the study. To secure confidentiality, an external IT consultant performed 
data extraction, replacing ID-numbers with a running number, the key to which 
remained undisclosed to the research group. 
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Paper II: This study did not gather sensitive or personally identifiable data and 
therefore did not require approval from the instances mentioned above.  
 
Paper III: REC west (2012/1091) and NSD (#31098) approved the study. Written 
informed consent was obtained from study participants, and pseudonym participant 




4.1  Paper I - Jansen K, Schaufel MA, Ruths S. Drug treatment at the end 
of life: an epidemiologic study in nursing homes. Scand J Prim Health Care 
2014;32:187-92. 
 
Drug prescriptions of 524 deceased nursing home patients were examined, focusing on 
palliative versus curative/preventive drug prescriptions in the last days of life.  
Median (range) age of population at death was 86 (19–104) years, 59% were women. 
On the day of death, 99.4% of the study population had active prescriptions; 74.2% of 
palliative drugs either alone (26.9%) or together with curative/preventive drugs 
(47.3%).  The most common palliative drugs were morphine (71.4% of patients), 
midazolam (55.0%), glycopyrronium (46.9%), and haloperidol (46.9%). Palliative 
drugs were associated with nursing home, length of stay > 16 months (AOR 2.10, 95% 
CI 1.12–3.94), age (1.03, 1.005–1.05), and a diagnosis of cancer (2.12, 1.19–3.76). 
Most initiations of palliative drugs and withdrawals of curative/preventive drugs took 
place on the day of death (Figure 3).  
 
Figure 3. Patients (%) with at least one prescription changed in the last 14 days of life  
 
We conclude that palliative drug therapy and drug therapy changes are common for 
nursing home patients on the last day of life. Frequent last day changes may point to 




























4.2 Paper II – Jansen K, Haugen DF, Pont L, Ruths S. Safety and 
effectiveness of palliative drug treatment in the last days of life - a 
systematic literature review. Accepted for publication in J Pain Symptom 
Manage.  
 
This systematic review assessed the evidence base of palliative drug treatment in the 
last days of life based on a literature search of seven publication databases.  
Of 5940 unique titles identified, 12 studies met the inclusion criteria (Figure 1). 
Heterogeneity of studies prevented meta-analysis. Seven studies were set in palliative 
care hospital units or hospices; with one of these also including home care patients. 
The remaining four studies were set at non-palliative care hospital wards. All studies 
were either exclusively or predominantly conducted in patients with a main diagnosis 
of cancer. Data was found for all primary outcomes (symptom control, adverse effects, 
survival), but only for the secondary outcome of level of consciousness. 
 
Five studies (four RCTs, two of them placebo controlled, and one prospective cohort 
study) assessed anticholinergics for death rattle, providing no evidence that 
scopolamine hydrobromide and atropine were superior to placebo. Five studies (two 
RCTs, three prospective cohort studies) examined drugs for dyspnea, anxiety, or 
terminal restlessness, providing some evidence supporting the use of morphine and 
midazolam. Two studies (one RCT, one retrospective cohort study) examined opioids 
for pain, providing some support for morphine, diamorphine and fentanyl. Eight 
studies included safety outcomes, revealing no important differences in adverse effects 
between the interventions, and no evidence for midazolam shortening survival. 
Overall, included studies were small scale and only two were considered to be of 
strong quality. 
We conclude that there is a lack of evidence concerning the effectiveness and safety of 
palliative drug treatment in dying patients, limiting guidance for clinicians on how to 
assist pharmacologically in a distinct and significant phase of life. 
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4.3 Paper III - Jansen K, Ruths S, Malterud K, Schaufel MA. The impact 
of existential vulnerability for nursing home doctors in end-of-life care: A 
focus group study. Patient Educ Couns 2016;99:2043-8. 
 
This qualitative study explored the experiences of nursing home doctors through three 
focus group interviews, focusing on the impact of their existential vulnerability.  
We found that nursing home doctors experienced making difficult treatment 
compromises in order to assist patients’ and families’ preparation for death, balancing 
these with their sense of professional conduct. They described lengthy negotiations 
and grief work processes demanding both patience and consideration, before they saw 
families reaching an acceptance of the futility of further interventions such as tube-
feeding or intravenous drips.  
Existential vulnerability also manifested as powerlessness mastering issues of life and 
death and families’ expectations. The doctors could fall short of consoling, of 
upholding assurances to patient or family, and described uncertainty responding to 
inquiries of prognosis. Even in cases where death was clearly imminent, the doctor 
could feel guilty of being the «bad informer» revealing the prognosis. 
Nursing home doctors balanced personal commitment with protective disengagement 
on the patient's deathbed. They described hesitancy engaging in conversations about 
death, and the need for a professional distance to the patient, that could lead to guilt. 
On the other hand, doctors’ time spent by the deathbed, either hearing patient stories, 
comforting with words, or daring to be informal with the patient could trigger a deep 
sense of satisfaction as well as improve professional coping.   
We conclude that existential vulnerability is experienced as a burden in the form of 
powerlessness and guilt in difficult treatment compromises, and a need for protective 
disengagement; but on the other hand also as a resource, in communication and in 




This thesis is based on three papers with different study designs. Selected 
methodological considerations are therefore discussed separately for the three papers 
in section 5.1, with ethical considerations finally considered jointly at the end of this 
section. Results are discussed in section 5.2.  
5.1 Methodological considerations 
Paper I was a historical cohort study investigating drug prescriptions to nursing home 
patients in their last days of life, Paper II was a systematic literature review assessing 
the evidence base for palliative drug treatment in the actively dying, and Paper III was 
a focus group study exploring the experiences of nursing home doctors, focusing on 
the impact of existential vulnerability. 
5.1.1 Paper I 
Design 
The historic cohort design was suitable for the descriptive and exploratory purposes 
we aimed for, and a realistic study design within the resource constraints of time and 
funding. It also avoids the effect that study participation may have on human behavior 
in a prospective study, (Hawthorne effect) i.e. the nursing home doctors’ prescribing 
behavior. On the other hand, the retrospective design is generally more vulnerable to 
confounding and bias than prospective designs.  
Data reliability and internal validity   
Reliability refers to the repeatability of findings, while validity refers to the credibility 
and applicability of the research. Internal validity asks whether the study credibly 
investigates what it is meant to, whereas external validity asks in what contexts the 
findings can be applied.  
Dates. Admission, discharge and death dates were cross-checked with data from 
patient administrative records, confirming good validity for these variables. 
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Medications. A complete set of recorded medication data of all deceased patients 
during their last stay was collected, including both regular and as-needed medications. 
This limits the selection bias of medication data in the study nursing homes. 
Prescribed medication may overestimate figures if they are interpreted as drug use, but 
more adequately reflect the doctor’s treatment decisions than given medication, 
particularly for as-needed medication. This is appropriate to the overall aim of the 
thesis of understanding the doctor’s role in EOL care in nursing homes. There may be 
a delay between when the drug change is decided and when it is documented in the 
EPR. Such a delay could lead to underestimation of discontinuation of curative drugs 
and prescription of palliative drugs near death in this study.  
Indication text had a high degree of completeness, present in 99.6% of all drug 
prescriptions on the day of death. Although drug indications are not standardized in 
nursing homes, the free text of indications is probably representative for everyday 
nursing home practice (pragmatic validity). 
Diagnostic information. All patients had at least one diagnosis registered in their EPR. 
The degree of completeness and validity for these data is unknown, but some 
observations do raise questions. For example, the 36.8% prevalence of dementia in our 
deceased study population was considerably lower than the 84.3% found in cross-
sectional assessment of Norwegian nursing home patients (11). This could point to 
under-diagnosis of dementia in our population. Another explanation could be that the 
prevalence of dementia in patients dying in nursing homes is considerably lower than 
that of the general nursing home population. Patients with a diagnosis of dementia had 
significantly longer duration of stay, meaning more patients without dementia died 
after shorter stays, and a higher turnover of patients without dementia. When only the 
deceased patients are counted the prevalence of dementia of the nursing home 
population may therefore be lower compared to a cross-section of the nursing home 
population. Underestimation of dementia could also occur if patients with dementia 
more often than those without dementia die elsewhere, most likely a hospital. I have 
not found figures from Norway regarding this, but this is from experience unlikely. 
We attempted validating the diagnoses of dementia with cognitive test scores (Mini-
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Mental State), but these were not sufficiently complete in the EPR to be used. The 
study started in the early years of EPR use in nursing homes, when both medication 
data and clinical data were gradually starting to be put in electronic form. This may 
have challenged data completeness.  
Definition of palliative EOL versus curative/preventive drug therapy  
As there is no standardized definition of what constitutes palliative drug therapy in the 
last days of life, such a definition had to be made by the research group, using both 
indication text and drug class/drug formulation (Table 1, Methods).  
The inclusion of specifically recommended (29, 138) palliative EOL drugs ensured 
that palliative prescriptions were not missed regardless of missing EOL key words in 
the indication text. In nursing homes, injectable antipsychotics and benzodiazepines 
may on occasion be used to treat neuropsychiatric symptoms of dementia. We found a 
median of two days from prescription to death for these two drug categories, making it 
likely that these prescriptions were issued for their palliative indications. While 
anticholinergics have several indications, including urinary incontinence, 
glycopyrronium and scopolamine in injectable form are seldom used for non-palliative 
purposes in nursing homes. Restricting the palliative prescriptions to injectables, we 
excluded prescriptions less specific to the dying patient, such as tablets, oral 
suspensions and patches.  
Out of 1306 palliative EOL prescriptions in our study, 1276 (97.7%) were identified 
by the drug class criterion alone, while 585 (44.8%) were identified by the indication 
text criterion alone. The drug class criterion was therefore the most decisive criterion 
in the definition of drugs relevant to the dying phase, but the joint definition of both 
criteria further increased sensitivity.  
As-needed prescriptions with no explicit palliative purpose and injectable formulation 
(21.3% of all prescriptions on the day of death) were intentionally excluded. The bulk 
of these prescriptions concerned oral medications such as laxatives or oral diuretics, 
most likely unsuited for a dying patient normally lacking the ability to take oral 
medications. As for the purposes of our main analytical categories of palliative versus 
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curative/preventive, I find this choice appropriate also in retrospect, although possibly 
introducing some misclassification bias. 
A strict dichotomy of curative/preventive versus palliative intention does not 
adequately reflect clinical practice, where drug therapy may serve both or unclear 
purposes, for example in the case of diuretic treatment of congestive heart failure, or in 
treating pneumonia with antibiotics for its exacerbation of dyspnea, delirium, or pain. 
In a Dutch study, 8 % of antibiotic prescriptions to nursing home pneumonia patients 
with dementia were given with a palliative intent. (149) Indication text key words 
would likely identify the palliative intention of such prescriptions, but perhaps not all.  
External validity  
Sample size was relatively large with 524 consecutive patients included, limiting 
selection bias. Due to the exploratory nature of this study, no power analysis was 
performed. A limitation of patient and nursing home sample size lay in restricting the 
study to a convenience sample of nursing homes using a particular EPR only used in a 
few nursing homes in Bergen at the time – “Geriatrisk Basis Datasett” (GBD). (150) 
Generalizability of our study is extended by the fact that the study population 
comprised patients from different types of wards. On the other hand, since nursing 
home was a predictor of palliative drug treatment in our results, and prescription 
patterns are known to differ across nursing homes, (100) the small number (N=3) of 
participating nursing homes could contribute to selection bias. International 
interpretation of results must also have in mind the characteristics and role of 
Norwegian nursing homes in health care mentioned in the background chapter of this 
thesis. There is possible comparability with countries with similar relative national 
health expenditures on LTC facilities, such as the Netherlands, Switzerland, Belgium, 
Denmark, and Sweden. Differences in people (patients and staff), organization, tools 
and technology, tasks, and environment are also known to play a role in drug treatment 
in nursing homes. (151) Despite organizational differences, similar barriers and 
strategies in EOL care for nursing home doctors have been shown between Norway 
and the Netherlands. (17)  
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5.1.2 Paper II 
Comparison with the systematic reviews in the NICE guidelines 
This systematic review addressed the prevalent and relevant issue of distress in the 
dying, and its pharmacological relief. It is comprehensive, including seven different 
databases, and employing broader inclusion criteria than has previously been done. 
Specifically, compared to the reviews on which the 2015 NICE guideline are based 
(30), paper II includes cohort design studies in addition to clinical trials and case-
control studies, and articles in seven languages in addition to English. While this sets 
the inclusion criteria bar for study design lower on the quantitative evidence-hierarchy, 
(152) affecting the strength of recommendation that may result from the review, it may 
be more sensitive in identifying studies that could contribute to the body of evidence.  
The number of systematic reviews in medical research is increasing, yet not keeping 
up with trials. (153) While our systematic review overlaps with some of the reviews in 
the NICE document, such overlap may serve important purposes. (154) For one, the 
eligibility process of included studies has clearly resulted in somewhat different 
studies included. Second, findings from systematic reviews can also benefit from 
replication. On comparison, I discovered what seem to be an error in the reporting of 
results in one of the NICE guideline reviews, as well as in a Cochrane review, which 
although concerns a result, I will mention here as an illustration of the importance of 
repeating systematic reviews. In the NICE guidelines, (30) a clinical benefit of the 
morphine plus midazolam combination compared to either drug alone for dyspnea is 
reported after both 24 and 48 hours compared to both drugs, while the study in fact 
reports no significant difference compared to morphine alone after 48 hours, but is 
indeed significantly better compared to midazolam alone, in terms of proportion of 
patients with uncontrolled dyspnea. The lack of difference for the morphine group 
after 48 hours is correctly presented in the table, but the text concludes that the effect 
is simply less pronounced after 48 hours. This may be a case of different interpretation 
of the results compared to paper II. However, a Cochrane review (155) to the contrary 
reports “without any difference when comparing the three arms after 48 hours”. This is 
in my opinion also an inaccuracy, although the lack of difference in dyspnea intensity 
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between groups supports a lack of difference in effect. Whether we regard these 
differences as inaccuracies or different interpretations between reviews, they seem not 
to have affected the main conclusions of neither the NICE nor the Cochrane reviews. 
Eligibility evaluation of full-text papers requires a template for data extraction, in 
order to understand their content, assess their quality, and report their results. We 
employed rigorous data extraction (McMaster critical review form) and quality 
assessment procedures (EPHPP). The EPHPP, although it grades the quality of 
individual studies, does not quantify the overall evidence across studies, nor does it 
grade strength of recommendations, nor is it easily applicable to individual outcomes. 
Quality of evidence across studies can be systematically graded based on a 
hierarchical assessment of study designs included in the body of evidence supporting a 
given association or recommendation. There are several options available to rate 
quality of evidence. (152) The GRADE system, (156) widely-adopted and used in the 
reviews of the NICE guidelines, is the only that considers strength of recommendation 
separate from quality of evidence. However, our study did not aim to develop 
guidelines, a process demanding far more than an overview of the evidence, and a task 
for larger research-, clinical-, and policy-making cooperatives to reach consensus on. 
The EPHPP quality assessment is more straightforward and was therefore deemed 
suitable to our ambition and purpose. 
5.1.3 Paper III 
Three central measures in the reporting and evaluation of qualitative studies are the 
notions of relevance, validity, and reflexivity. (157, 158) While relevance is addressed 
both in the background and in the discussion of results, validity and reflexivity will be 
addressed here.  
Reflexivity and preconceptions  
Reflexivity is defined as “An attitude of attending systematically to the context of 
knowledge construction, especially to the effect of the researcher, at every step of the 
research process”. (157) Reflexivity is a frame of reference in which to approach 
discussions particularly related to limitations and strengths of the study, and the 
 43 
transferability of findings. I have therefore attempted to demonstrate reflexivity in all 
sections of the methodological considerations with respect to paper III. In this section, 
however, I focus on the role of my preconceptions, and the impact of my own 
experiences on developing the research question, analysis and interpretation of the 
study.  
For paper III, I initially set out to explore the challenges of the nursing home doctors 
in EOL care work, with a presupposition that difficulties abound in this work; that in 
exploring these difficulties, they may be better understood; and that sharing this 
understanding would be helpful to nursing home doctors and their dying patients. 
Paper I added to suspicions that prognostication of death might be a central difficulty. 
My own experiences of difficult yet sometimes profoundly touching encounters with 
dying patients and their families in crises have, since I started working in nursing 
homes in 2007, both challenged and rewarded me both on a personal and professional 
level. I may therefore have had a special awareness for aspects of EOL care that are 
personally and professionally challenging yet rewarding.  
On seeing glimpses of vulnerability in the stories of doctors interviewed in the first 
interview, I realized that the research question was perhaps not best attacked directly 
by asking for “challenges”, even though I may have been looking for these initially. 
As was pointed out to me by fellow researchers, limiting the research question to 
“challenges” may simply have been an expression of my own preconceptions. Asking 
for “experiences” both provided an indirect and perhaps less intimidating opening 
even when looking for challenges, and importantly, opened for the observation that 
“challenges” may not be neither the most relevant nor most common descriptor for 
doctors’ experiences.  
As a central aid to reflexivity throughout the research process, and supporting analysis 
as well as my own learning, a decision trail was used. (159) This document included 
all email correspondence, supervision minutes, and developments to the study from 
conception to publication.  
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Recruitment and participants 
Recruitment was purposive, selecting participants with the aim of diversity with 
respect to age, gender, working experience, and nursing home institutions. The line 
between purposive and convenience sampling may be unclear, however. As an 
example of difficult recruitment in paper III, an attempt to organize a focus group with 
doctors from rural nursing homes in northern Norway was unsuccessful. In the last 
interview, all participants belonged to a fixed group meeting for continuing education 
(CME) purposes, and no changes to the groups was attempted made, as its 
composition was deemed satisfactory. The second focus group was a combination of a 
CME group and other participants, while the first group was composed entirely by 
individual selection of participants. The concept of information power has been 
suggested as a more relevant factor than the number of participants and interviews for 
the ability of qualitative studies to contribute new knowledge. (160) The more 
information power in a study, the fewer participants are needed and vice versa. 
Information power is facilitated by the narrowness of aim, sample specificity, quality 
of dialogue, by whether established theory is applied and single-case (versus cross-
case) analysis is aimed for. Information power in paper III was thus facilitated by a 
narrow aim of addressing existential vulnerability, a specific sample of nursing home 
doctors with experience from working with dying patients, good quality dialogue, and 
the application of existential theoretical perspectives in analysis. Cross-case analysis 
of diverse experiences of several nursing home doctors in EOL care demanded more 
participants than would a case study. Overall, and in light of these aspects of 
information power, I judge sample size to have been appropriate. 
Analysis 
Systematic text condensation (STC) has been developed by Kirsti Malterud, a 
researcher and colleague at the Research Unit for General Practice in Bergen. This 
method for qualitative text analysis has been clearly and didactically described. (146) 
Other qualitative analytic methods apt for descriptive thematic text analysis could have 
been used such as Grounded Theory, (161), Template analysis (162), or Interpretative 
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Phenomenological Analysis (163). Methods of longitudinal analysis such as Narrative 
analysis could have also been employed, as data was rich in terms of stories.  
STC is inspired by Giorgi’s psychological phenomenological analysis and, as most 
qualitative methods, is founded on phenomenological philosophy. It is however 
intended more as a procedure than a theoretically dedicated method. (146) STC 
therefore grants researchers much flexibility with respect to the theoretical perspective 
to be applied upon the research question, and even to refrain from applying one. 
Theoretical frameworks may be applied in different manners and at different stages in 
the analytic process. (164) In paper III, the decision to apply a theoretical framework 
was made toward the final stages of analysis, where we felt the need to sharpen 
analysis with respect to emerging vulnerability issues. Theory in paper III was chosen 
based on the interests and acquaintances of the first and last authors with existential 
perspectives in philosophy and psychology. In particular, my co-supervisor and main 
qualitative supervisor Margrethe Schaufel had done previous research on how 
existential challenges affect doctor-patient-interactions and decision-making processes 
at the cardiology ward. In her thesis, she applied the existential philosophical 
perspectives of the Norwegian philosopher Arne J Vetlesen. I became familiar with the 
work of the oncologist David W Kissane through exploring research literature on 
existential distress in palliative care. Kissane builds upon the work of existential 
psychiatrist Irvin Yalom, whose work I was also acquainted with.  
Naturally, other theoretical perspectives were discussed, such as Shared Decision-
Making, (165) and would have taken analysis in different directions, underscoring the 
active role of the authors in shaping the product of qualitative analysis. 
Transferability 
Transferability is synonymous with external validity, and concerns how the findings of 
the paper may be applied in other settings. (148) Although we believe international 
comparisons to our results are reasonable within a Western cultural setting, doctor’s 
experiences are likely to be influenced by factors such as doctor availability and EOL 
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care competence, role of nursing home in health care, and cultural differences in 
attitudes toward death and dying, communication, and faith or worldview.  
In particular, doctor availability and staff resources are likely to allow more time for 
patient and family dialogue, and the reflection and self-care that have been shown 
central to coping with the emotional, physical, and existential demands of EOL care. 
(116, 122, 126, 166) Although it is difficult to find comparable figures of doctor 
availability in LTC facilities internationally, as mentioned earlier, relative health 
expenditures in LTC facilities likely indicate differences also in this regard. (13) 
The existential perspective is in a sense culturally inclusive, by taking as a starting 
point the most basic elements of the human existence conceivable, and shared 
vulnerabilities across humanity. This may make findings relevant to a wider audience, 
across cultural or religious background. Regardless of its inclusive aim, the 
philosophical/psychological language used in the existential tradition may also feel 
strange or unaccustomed to some, as it long did to me. Discussing issues surrounding 
death will likely often be difficult and special in spite of shared concepts and language. 
Kissane developed a typology for doctors to be able to recognize, talk about, and 
manage existential distress in patients. I have attempted to broaden the relevance of 
this typology by applying some of its ideas on the experiences of nursing home 
doctors working with dying patients. 
5.1.4 Ethics 
While this thesis ultimately aims to benefit the nursing home patient and their closest 
kin, it primarily addresses the efforts of the nursing doctor, central in the staff team 
working to this end. While this aim is easily justified, the contribution of research 
must also exceed the burden of its process. This first implies a number of 
considerations regarding participants and subjects in the research. There is fortunately 
no burden to patients in any of the studies.  
The stories the focus group participants told were sometimes evidently difficult to 
share, revealing of shortcomings and weaknesses, and eliciting emotional reactions. 
Even so, the feedback received was positive and encouraging, and many participants 
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expressed a sense of meaningfulness of participating. Anonymity was ensured through 
pseudonym participant names, and secure storage of audio recordings and 
transcriptions, in a protocol approved by the regional ethics committee and the 
Norwegian Social Science Data Services. Recruitment was sought to be made as 
confidential as possible in the first focus group, where the group did not meet regularly 
for education purposes, as most participants did in the last two groups. I was 
acquainted with several of the participants in the first and second focus groups from 
previous work in the same municipality, and they may therefore have felt more of a 
pressure to participate when I asked them than if I had not known them. This may also 
have affected what these participants shared in the interviews, for example by a wish 
to please me. 
5.2. Discussion of results 
5.2.1 The doctor’s role in EOL care in nursing homes – a position of uncertainty 
I will discuss below selected issues related to the results of the studies in this thesis. As 
a unifying perspective, I will demonstrate how the nursing home doctors’ position in 
EOL care work is characterized by uncertainty in several distinct regards. I will 
address these in turn. 
Uncertainty prognosticating death 
Although this thesis does not specifically investigate prognostication, some findings 
point to uncertainty regarding prognostication, or rather, that death comes unexpected. 
In paper I we found a marked increase of drug therapy changes on the day of death. If 
medications are being continuously reviewed with respect to relevance, such as ideally 
is the case, then such a marked increase of drug changes points to death coming 
unexpectedly. Doctors interviewed in paper III also expressed uncertainty regarding 
recognizing the dying phase.  
Survival prediction studies on home-dwelling or hospice patients with cancer 
dominate, for whom several models of prognostication have existed for years, based 
on function and performance scales, symptoms and clinical or laboratory 
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measures.(167-169) “Would I be surprised if this patient died in the next 12 months”, 
sometimes called the “surprise question”, has been recommended in the UK to identify 
patients at high risk of death who might benefit from palliative care services, (170) but 
performs poorly to modestly as a predictive tool for death, and worse in non-cancer 
illness. (171) Disease trajectories for non-cancer diseases such as dementia and organ 
failure, more prevalent than cancer in nursing homes, are harder to predict. (172-174) 
The eldest patients above 85 years of age have been underrepresented in 
prognostication studies, but measures of physical performance have been found to be 
predictors of survival also in this group. (175) Prognostic tools to estimate 6- and 12-
month mortality in nursing homes have nevertheless been shown to perform fairly 
well. (176) 
The role of professional background and experience in prognostic ability of death is 
uncertain. (177) In the last month of life, actual survival and clinical prediction by 
doctors are correlated, but doctors are systematically optimistic in their prognoses. 
(178-180) In a study from an inpatient palliative care unit (PCU) in Ireland, in a 
population of median actual survival of 20 days (range 1-635), no staff group placed 
patients in the correct survival category more than 50% of the time, nursing and junior 
medical staff being more accurate than senior doctors and nursing assistants. (181) The 
difference compared to senior doctors was attributed to more frequent assessment 
opportunities. This contradicts a previous study finding that prediction ability 
improved with doctor experience. (182)  
On the brighter side, survival predictions become better toward the final days of life; 
(179) nursing home doctors have been shown to be accurate in more than 90% of their 
prognoses in the last seven days of life. (183)  
Uncertainties related to non-cancer conditions and in particular dementia  
As paper I also showed, being prescribed palliative drug therapy on the day of death 
was associated with a diagnosis of cancer. In other words, patients with non-cancer 
conditions may present an additional uncertainty to nursing home staff. Unpredictable 
illness trajectories of non-cancer illnesses such as chronic obstructive pulmonary 
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disease (COPD), heart failure, and dementia challenge not only prognostication, but 
also recognising and meeting the changing needs of pharmacological symptom relief, 
adding to uncertainty. (184, 185)  
Advanced dementia is a terminal illness particularly prevalent in nursing home 
patients, challenging communication, symptom assessment, prognostication, 
autonomy and decision-making. (186-189) Dementia leads to uncertainty regarding 
treatment decisions, appropriate care setting, and care provider, and timing of 
palliative interventions. (190) Anticipatory prescribing of palliative drugs in acute 
geriatric wards has been shown to be less frequent in the last 48 hours of life of 
patients with frailty or dementia than in those with cancer. (191) 
Dementia was the most common diagnosis of the deceased nursing home patients in 
paper I, but was not independently associated with palliative drug therapy (or the lack 
of). A negative association could have been expected, as dementia as mentioned poses 
particular challenges to proxy assessments in EOL care. Likewise, in all dying patients 
with reduced capacity to communicate, recognition of pain and other symptoms must 
be done with proxy assessments. The validity of proxy assessments can be questioned, 
but alternatives are hard to imagine. Communication difficulties associated with 
dementia are known to challenge decision making in the nursing home, (186) and may 
also have contributed to the late drug changes observed in paper I.  
Diagnostic uncertainty in the nursing home setting 
Nursing homes and the primary health care setting in general lack diagnostic resources 
compared to hospitals, such as diagnostic imaging, on-the-hour blood analyses, 
specialist second opinion, etc. The nursing home doctor hence works in a greater 
diagnostic uncertainty, which, if accepted, may spare the patient unnecessary 
relocations or invasive procedures, but also challenge treatment decisions. On the 
other hand, fewer doctors will be involved in the medical care provided in nursing 
homes and the primary health care setting compared to hospitals. This provides 
continuity of care, and may contribute to better knowledge of the patient, facilitating 
communication and therapeutic alliances.  
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Uncertainty regarding effectiveness and safety of drugs 
Regarding knowledge on effectiveness and safety of palliative drug therapy, almost all 
studies included in paper II were conducted in the oncological or palliative care unit 
setting. This points to a particular lack of research-based knowledge on EOL care in 
the nursing home setting. (192) 
Paper II reveals the marked lack of research evidence of effectiveness and safety of 
drug therapy in the dying. Specifically, we may not know which is the most effective 
and safe pain-relieving drug therapy option in the dying, and anticholinergics are 
probably not worthwhile for death rattle.  Doctors must therefore base clinical practice 
on experience, and from research on other patient groups.  
Not all distress of dying may be fully relieved. Staff may fail to recognize symptoms 
and complaints, fail to adequately treat them, or the symptoms are simply beyond 
remedy. In a Norwegian study, on the day of death, while the administration of 
opioids, midazolam, and anticholinergics increased and were associated with some 
symptom relief of pain, anxiety, and depression, most symptoms were still present 
after treatment, and moderate to severe dyspnea and death rattle increased. (27) In a 
Swedish study, while pain was the symptom with the highest proportion of symptoms 
relief, other less prevalent symptoms were also less well-relieved. (26) Poor symptom 
control at the EOL despite extensive drug treatment has also been found in US and 
Dutch nursing homes. (193-195) Doctors may attempt to treat intractable symptoms by 
sedation. (196, 197) To some, the inability to relieve suffering at the EOL is an 
argument for hastening death or euthanasia. (198) Doctors and other staff working 
with dying patients must therefore be prepared for the possibility that not all symptoms 
may be fully relieved.  
On the other hand, treating physical symptoms alone may not be the main determinant 
for quality of dying in nursing home patients. In after-death interviews from LTC 
facilities in the US, pain and dyspnea were not associated with a poorer quality of 
dying as perceived by families of deceased residents, and could alert staff to the need 
for care. (199) Unfulfilled needs of doctor communication, emotional support, and 
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being treated with respect, (200) are hardly met by drug treatment. The EOL care 
experience has multiple domains apart from physical symptoms: quality of life, 
emotional and cognitive symptoms, functional status, ACP, continuity of care, 
spirituality, grief and bereavement, and caregiver well-being. (201) 
If drug therapy does not work, and the doctor is stripped of a central tool and power, 
how does this impact the doctor’s role in EOL care? We move on to the uncertainty 
expressed by doctors interviewed in paper III.   
The doctor’s uncertainty and existential distress working with dying patients 
The certainty of death contrasts the uncertainties surrounding it. Contemplating the 
possibility of dying opens for a wide variety of concerns often termed existential 
distress. Such contemplation and distress is inextricably linked to being human, 
mortal, and in particular to facing life-threatening illness. As a general human 
vulnerability, existential distress is reasonable to expect also in staff working with the 
dying, although this has been less studied. (127) 
Paper III shows how existential vulnerability, our common vulnerability facing threats 
to our existence, presents in the experiences of nursing home doctors working with 
dying patients. It presents as feelings of powerlessness, uncertainty and guilt facing 
prognostic and palliative challenges, in the difficult balance of treatment compromises 
with next-of-kin with professional conduct, and in the occasional need for protective 
disengagement from difficult situations. In the view of Kissane’s existential typology, 
powerlessness may be enhanced by the doctors' own need for control, and the shared 
human anxiety for death, the stigma of death, and doctors' sense of responsibility may 
contribute to vulnerability.  
5.2.2 End of life care strategies for nursing home doctors 
In a situation characterized by the uncertainties discussed above, how should nursing 
home doctors cope? Based on the findings in the three studies comprised by this thesis, 
I propose four ideas to meet the mentioned uncertainties of EOL care work in nursing 
homes:  
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1. Research in EOL care and nursing homes  
2. Integrated ACP and grief work dialogue with patient and family  
3. Self-reflective practice  
4. Adjusting interventional strategy, relational strategy and focus of self-
awareness with deteriorating prognosis 
1. Research in EOL care and nursing homes 
When not reducing uncertainties, research may help us understand them better. Paper 
II confirmed a need for research in the palliative treatment of the dying. There is an 
abundance of methodological and structural challenges to conducting research in 
palliative care, providing some explanation for the small number of studies we found 
in our review. Close to death, high attrition rates in particular limits sample size in 
palliative care studies. (202) This was of consequence in several of the included 
studies in paper II (203-205).  
Generally, central challenges exist in the domains of study design, assessment and 
classification of symptoms and signs, obtaining informed consent, recruitment and 
engaging stakeholders, ethical issues, funding, and policy issues. (206-210) 
Researchers also describe public and professional apprehensions concerning 
participant burden, misunderstandings of EOL care, and aversions to serious illness to 
be significant barriers. (202, 211) International collaboration is becoming increasingly 
important to address priorities in EOL care, and for funding bodies to share 
experiences from successful funding frameworks. (212) In heart failure palliative care 
research, as an example of one of the better studied non-cancer conditions, 
unpredictable illness trajectories challenge the identification of the dying phase, and 
therefore participant eligibility, user involvement, and contributes to participant 
attrition. (213) 
Distinguishing between symptoms such as pain, anxiety, and restlessness in the 
actively dying is not easy, and neither is symptom assessment of patients with reduced 
ability to communicate, such as commonly in dying patients or patients with dementia. 
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Assessments for these patients rely on the ability of staff to interpret behaviours and 
signs such as restless movements, sounds or facial expressions. The proxy judgement 
of distress in these situations is vulnerable to misunderstanding (214-216). However, 
clinicians may not always need to distinguish between symptoms with overlapping 
presentation, since drugs often have multiple or sedative effects that may treat several 
of them. As examples in paper II, opioids or midazolam are used to treat both dyspnea, 
pain, and anxiety. Such overlap of both symptoms and pharmacological effects may 
make treatment strategies simpler, but complicate the design of RCTs, and research in 
general in this population.  
The two trials studying respiratory tract secretions in the dying, known as death rattle, 
were placebo-controlled, (217, 218) a design presenting particular challenges in EOL 
care. Being an observable sign as opposed to a subjective symptom, the impact of 
death rattle on the patient may be questioned, and therefore the need for its 
pharmacological relief. A placebo-controlled trial may be unethical when a difference 
of effect between the “real” and the placebo intervention is clearly expected. For a 
clinical trial to be ethical there needs to be “equipoise” between the groups compared - 
an epistemic state of indifference. (219) If not, the placebo group greatly risks 
suffering harm, for example by having more untreated pain compared to an 
intervention group testing opioids for pain, making a study ethically unacceptable. 
(220) When the expected effect of the active intervention is more uncertain, the 
potential harm of a placebo group in comparison is also lesser, and equipoise between 
study treatment groups is greater. The use of placebo-control to study death rattle is 
perhaps therefore not as ethically controversial as in the case of the more subjective 
complaints, for which we did not find RCTs.  
Importantly in palliative care, placebo effects depend on healing patient-therapist 
relationships and context of care. (221-223) These effects do not imply deception, as 
the placebo concept often is associated with, but may represent tangible benefits to 
patients. The skills and contexts conducive to them must therefore not be dismissed, 
but studied and cultivated. On the other hand, pharmacological treatments that add no 
benefit compared to the therapeutic relationship alone may not only be unethical but a 
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waste of resources. The studies by Heisler and Likar exemplify that a placebo control 
may be acceptable also in the dying population, as long as equipoise between 
comparison groups is respected. Crossover studies, where study subjects cross over 
between interventions compared during the study, or add-on studies, where subjects 
receive standard treatment plus the experimental treatment, can also make placebo 
controlled studies more ethically acceptable, but are difficult to perform in the dying 
population as observation time is limited. Nevertheless, one of the RCTs included in 
paper II, although not placebo-controlled, was in fact a crossover study. (205) The 
alternative to placebo control is an active control, which was used in the five other 
RCTs included. (204, 205, 224-226)  
Challenges and proposed solutions to conducting research in nursing homes to a large 
extent mirror palliative care research challenges in general. For qualitative research, 
identified issues have been: informed consent, finding opportunities to conduct 
interviews, involvement of care home staff and residents' families, and maintaining 
privacy during interviews. (227) In addition, non-participation of nursing homes in 
EOL care research has been associated with the number of deficiencies (as listed in a 
public health department record) and a higher key staff turnover. (228) This last 
finding, if generalizable, confers an important risk of selection bias on nursing home 
research. Relating this to paper I, although the EPR used in the study nursing homes 
was used free of charge to the nursing homes in the study period, a selection of 
particularly resourceful nursing homes cannot be excluded.  
The last two decades have seen a growth of research in EOL care in nursing homes. 
(229) Nevertheless, studies are few and mainly observational, and in need of relevant 
and validated measurement instruments for patient outcomes. (192) Trials of palliative 
care interventions assessing patient outcomes have been called for, particularly outside 
USA, (230) where organizational factors challenge comparison to other countries. 
(231, 232)  
A number of strategies for dealing with the challenges of palliative care research in 
general have been suggested in the domains of study design, sampling, conceptual, 
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statistical, and measures and outcomes. (208, 209) Clinical trials in a palliative care 
population have shown not only to be feasible, but even to represent a positive 
experience for patients. (233, 234) Gysels suggests a model of research in palliative 
care, typified by participatory study designs, with tailored data collection from 
supported and supervised participants, and where immediate patient benefits are 
obtained in the form of empowerment, self-validation and an opportunity for altruism. 
Where objectifying and instrumental research is often framed in opposition to person-
centered and empathic care, such a model allows for a culture that is open to research, 
and a research that is not in conflict with, but is embraced by the principles of care. 
(233) 
To improve palliative care knowledge in nursing homes, creating a research culture in 
nursing homes and palliative care services, (235) and seeing the value of a range of 
study designs depending on the research question, including also qualitative designs 
and action research, has been proposed. (236) 
2. Integrated ACP and grief work dialogue with patient and family 
This thesis points to many changes to drug therapy in the last day of life of nursing 
home patients, indicating that death comes unexpectedly. Unexpected is relative. In 
nursing home LTC, where patients have a short remaining life-expectancy, death 
should in one sense not come as a surprise for any patient. It may instead be that the 
major impediment to preparing for the dying phase with appropriate changes to drug 
therapy is not the diagnostic ability itself, and the uncertainty of interpreting objective 
signs of dying in the last days of life. As mentioned, such prognostic ability has been 
demonstrated in the last days of life in the nursing home, and in several groups of 
staff. (183) A major impediment to “seeing” the dying stage may instead be the lack of 
communication with patient and family with respect to prognosis in good time before 
dying. In time before the dying phase, the staff should respond to uncertainty of 
prognosis by advance discussions of goals of care and treatment with the patient 
and/or family (ACP). Communication and treatment negotiations with family were 
central in the stories told by nursing home doctors in paper III.  
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ACP dialogue with patient and family potentially decreases the need for futile 
treatments. An example of likely futile treatment is raised in paper II, as the effect 
drug treatment of death rattle is not proven to be better than placebo, calling for non-
pharmacological interventions such as information to family. Studies have shown a 
positive effect of early decision-making (ACP) on EOL care both in LTC and across 
settings of care, on patient and family satisfaction, reducing hospitalizations and costs, 
and improving concordance between patient's preferences and treatments received. 
(79, 237-240) Nursing home doctors also feel ACP discussions facilitate future 
decisions on medical treatment and EOL care. (117) While doctors have the formal 
responsibility for EOL decision making together with the patient and family, the 
nursing staff also need to be involved as discussion partners and sources of knowledge 
of the patient. (241) Patients lacking decision-making capacity are sadly lacking from 
ACP studies in nursing homes, (64) a large patient group in nursing homes. Doctors’ 
concern for and judgement of these patients’ best interest may come in conflict with 
next-of-kin’s opinions, as shown in this thesis, and also in other interview studies from 
Norway. (63, 68) If all caregivers and staff are confident in honoring the patient’s 
wishes, they may face death together with peace. A good ACP process, allowing for 
the doctor and staff to know the patient, mapping and settling the patient’s care and 
treatment goals, may thus provide a counterweight to the uncertainties mentioned.  
However, doctors interviewed in paper III described discussions not only for treatment 
decision-making, but also for preparing patients’ and their families for the death of the 
patient. The task of preparing patients and their families or informal caregivers for 
death is sometimes called promoting “preparedness for death”, or “pre-loss grief” 
work. The presence of pre-loss grief, and low preparedness for death appear to be risk 
factors for adverse bereavement outcomes such as complicated grief, and post-loss 
depression and anxiety, and interventions show a tendency for increased caregiving 
time to increase preparedness for death. (242) Preparedness is closely related to being 
“peacefully aware” of the terminal nature of illness, (243) and Kissane’s “adaptive 
adjustment” to the existential distress of death anxiety. (131) While the concept of 
preparedness focuses on family and caregivers, cancer patients that are aware of their 
terminal illness and also feel “at peace”, have lower rates of psychological distress and 
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higher rates of ACP, higher overall quality of death, and their surviving caregivers are 
healthier physically and mentally six months after their loss, compared to those who 
were not peacefully aware. (243) The fact that palliative drug treatment in paper I was 
associated with the longest duration of stay may support that increased caregiving time 
increases preparedness for death, and that getting to know patients and their families 
improves care. Dialogue with patient and family is likely to support a recognition of 
and appropriate response to the dying phase. Without an early-starting and continuous 
dialogue with patient and family, palliative changes to drug therapy may come 
unexpected to unprepared family, and demand more time-consuming communication 
efforts from the staff than when the prospect of dying, its course, care strategy, and 
feelings are shared and discussed in advance. Restraints of time may then impede 
choosing a palliative strategy.  
The dialogue with patient and family described by the nursing home doctors 
interviewed in paper III, integrated decision-making and grief work, and was described 
as a continuous and sometimes arduous process. A process perspective may be useful. 
Oncologists who view EOL care communication with dying patients as a process 
addressing patient and family acceptance of dying report increased job satisfaction. 
(244) A palliative response still requires that the doctor have knowledge of life 
expectancy considering the patient’s health condition, as well as knowledge of time-
to-benefit for all therapies. (43) A bedside doctor’s assessment ensures a cross-
disciplinary acknowledgement of the dying phase, and contributes to appropriate 
prescribing, but is difficult to achieve out-of-hours in nursing homes. Based on this, 
increasing doctor availability may have the potential to improve the early 
pharmacological response to the distress relief needs of dying patients in the nursing 
home.  
What does a palliative strategy, and an early palliative response in drug therapy 
concretely mean in the nursing home in terms of drug changes? It cannot mean that all 
patients are to be prescribed parenteral morphine as needed, as this would likely 
increase inappropriate use. Symptomatic as-needed prescriptions must be reserved for 
the events of deterioration in condition, but with a low threshold for prescription. It 
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cannot mean either that all curative/preventive medications should be discontinued the 
moment you are admitted to LTC, as some of these will be appropriate. However, 
from the moment of admission, drug therapy must be reconsidered in the view of 
limited life-expectancy, and ACP dialogue must be started with patient and family. 
Doctors cannot postpone it until the dying phase is certain to prepare their patients and 
their patient’s families for it. But as I will discuss next, doctors must also prepare 
themselves. 
3. Self-reflective practice  
The task of preparing for death is also relevant to health care professionals working 
with dying patients. Working in EOL care, health care professionals must endure the 
cumulative loss of many patients, some relationships, stories or encounters having 
profound emotional impact, making lasting impressions. (134, 245) Such stories and 
impressions were explored in the interviews with nursing home doctors in paper III. 
Health care professionals working in EOL care risk burnout, compassion fatigue, and 
poor quality of care, to which existential distress has been linked as a key contributor 
(126, 246). 
The need for a professional distance from death and dying was described by doctors in 
paper III. In view of Kissane’s existential perspectives, such need for distancing from 
death and dying is an expression of human beings’ anxiety of death. Fear and 
uncertainty before death, subtle or ignored as it may be, is at the core of existential 
vulnerability. Mortality is the ultimate vulnerability. The American psychiatrist Irvin 
D. Yalom has been central in the development of a whole field of psychology called 
Existential psychotherapy, identifying existential concerns surrounding death, 
freedom, isolation and meaninglessness as primary sources of all major psychological 
defense mechanisms. (130) Fear of death is thus potentially a powerful force affecting 
our own emotions, behaviour and thinking, as well as our relationships with others. It 
has the potential to compromise patient care. (126) Death rattle is potentially an 
example – likely a false alarm for patient distress, but a concrete reminder of the 
proximity of death, and perhaps therefore, difficult to endure for family and staff. 
(247, 248) 
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Avoiding seeing death and clinging to cure is an escape not only for the patient or 
family, but also for the doctor and staff. In order to “see” death, we must bare to see it. 
To acknowledge that death is irreversibly coming, we must accept that even our most 
heroic curative efforts to prolong life, are not enough; that our most well-intended 
palliative efforts to alleviate suffering and improve quality of life, has limits; and even 
that our most genuine personal presence in warm-hearted consolation, can only reduce 
the burden so far. We must let go. (249) If we can manage to not let the fear of death 
hinder our recognition of the patient as dying, this in turn could promote the palliative 
adaptation of drug therapy, and other aspects of care depending on this recognition. In 
support of this last point, self-reports from hospital doctors confirm that awareness of 
impending death is correlated with more communication with patients and family. 
(250) Doctors must embrace uncertainty to cope with it. (251, 252)  
The highly-selected group of people working in EOL care may, with the right coping 
skills and self-care strategies, also experience rewards of facing existential challenges. 
(126) Simply relying on disengagement and professional distance for self-care may 
impair communication and make patient encounters less rewarding. (244) Nursing 
home doctors interviewed in Paper III described how, through compassionate 
engagement and revealing a shared human vulnerability, they experience facilitated 
communication and coping better in their jobs. Daring to be vulnerable with the 
patients thereby facilitated EOL care, and allowed for shared meaningful experiences. 
Doctors also described positive experiences of gratitude, peace, awe, and reverence by 
the deathbed. Potential benefits of working with the dying have also been described 
elsewhere. (126, 253) When viewed as an opportunity for reflection on one’s own life 
experiences and mortality, or to find meaning and perspective, EOL care work can 
reward personal growth, a sense of personal accomplishment and fulfillment, greater 
meaning in life, an increased capacity to live in the present, appreciation for life, 
reduced fear of death, increased compassion, and improved quality of life. (126) 
Perhaps due to these potential benefits, doctors working in palliative care have low 
burnout levels compared to other specialties. (254)  
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Key to helping ourselves as health care professionals endure the existential distress, 
uncertainties and difficulties that we face in EOL care, is improving self-awareness of 
how we are affected by death and dying. (126, 166, 255, 256) But what does self-care 
and self-awareness involve? Studies of nurses have emphasized seeking colleague 
support, taking time off from work, and formal supervision. (126) According to 
Kearney, self-awareness involves both self-knowledge, and a “dual awareness” of 
simultaneous attention to the needs of the patient, the work environment, and one’s 
own subjective experience. (257) Reflection enables learning from complex situation, 
both after and during experience, and may be developed with practice. (258) Useful 
activities to enhance self-awareness include participation in educational projects, peer-
support and reflection groups, engaging in mindfulness meditation and reflective 
writing. (257, 259, 260)  
4.  Adjusting interventional strategy, relational strategy and focus of self-awareness 
with deteriorating prognosis 
In Table 4 and Figure 4, I attempt to integrate some of the findings of the studies in 
this thesis in a conceptual framework of a gradually deteriorating patient condition and 
prognosis. For each prognostic stage, I suggest a strategical perspective for 
intervention / drug prescription, for relation to patient and family, and focus for the 
reflective practice of the doctor’s self-awareness. The choice of strategy is at each 
stage individually adjusted by the patient’s goals of care. 
A phased transition of palliative care with curative treatment is commonly adopted, 
and probably the most appropriate model for EOL care. (261) Therefore, although I 
present these as discrete steps in order to accommodate findings, the conceptual and 
idealized steps in Figure 4 and Table 4 clearly overlap. They are not a comprehensive 
instruction for prescription, communication and decision-making, nor for self-
reflection in EOL care. Table 4 presents a selection of concepts that I can relate to the 
findings of this thesis, particularly to paper III. I focus on interventional strategies on 
drug therapy, as non-pharmacological interventions have not been studied this thesis. 
The figures do not incorporate the phase of bereavement care that mainly comes after 
death, for reasons of simplicity, and as this phase has not been the focus of this thesis. 
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On admission to LTC in the nursing home, the patient has an average prognosis of 
months to years. Both curative and preventive treatments may generally be 
appropriate, but the nursing home doctor needs to reconsider preventive drug 
treatment in the light of limited prognosis and the patient’s wishes. Early ACP 
conversations involve getting to know the patient and family, and where they stand 
with respect to accepting their condition and outlook on life, and what issues are 
important to them at this point. Based on the latter, the ward strives to provide a 
meaningful environment, activities and level of stimuli. I propose that a relevant focus 
for self-reflective practice is the stigma of death elicited by raising the issue of dying 
with patient and family, and the meaning of dignity for patient, family, and 
doctor/staff.   
As the illness trajectory moves on, for example by worsening of pulmonary, cognitive 
or cardiac function that may be either gradual or fluctuating, there is a supportive aim 
in treatment. The patient’s goals of care are translated by the doctor into concrete 
medical options, considerately informing and negotiating with patient/family. Most 
preventive medicines should be discontinued by now, and efforts are made to reduce 
medication and intervention load. Infections are treated by antibiotics, but perhaps not 
intravenously, and hospitalizations are generally avoided. Treatment negotiations may 
be difficult. I suggest as a focus for self-reflection the impact of difficult treatment 
compromises made with family, on the doctor’s idea of a professional conduct. 
When either the patient is recognized as in the final days of life, or has severe and 
specific need for symptom control, doctor and staff do not give up on the patient but to 
the contrary heighten their engagement, concentrating their attention on close 
symptom monitoring, providing patient/family with information and support, striving 
for care goal implementation and adherence. Palliative attempts may fail, and the 
patient will sooner or later deteriorate further. Promises may have been made to family 
that cannot be kept. I suggest that a useful focus for self-reflection at this stage is the 
personal impact of failed palliative attempts and promises, ensuing feelings of 
powerlessness, the need for control, and how the doctor should and should not take 
responsibility for the course of illness. 
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Table 4. Interventional strategy, relational strategy and focus of self-awareness with 
deteriorating prognosis.  
 
 
The final moments of life are powerful and evocative. The patient’s condition is 
clearly poor and death is likely imminent within hours. A non-intervention strategy 
may be applied to treatment, relationship with patient and family, and as a focus for 
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self-awareness. A strategy of non-intervention does not mean abandoning symptom 
control, or disengagement from the patient and family. Care at this stage is, more than 
ever, receptive to the needs of the patient and family. However, there may be a shared 
acceptance between family and staff to let “nature take its course”, respecting the 
dying phase as a natural and unmedicalized part of life. Pharmacological interventions 
should be stable, new interventions preferably avoided, and the doctor’s efforts 
concentrated upon availability to family and staff for information and assessment, and 
securing appropriate anticipatory prescribing. In the case of refractory symptoms, 
sedation may be an option. Palliative sedation, by dulling all experience regardless of 
nature, runs the risk of representing over-treatment. However, to the extent that the 
patient already has reduced consciousness, sedation seems a little invasive 
intervention. I suggest that the ideal relational strategy with patient and family in such 
a situation, where neither words nor medical interventions suffice or even are required, 
is that of peaceful presence. Such presence embodies a doctor who has reflected on his 
or her personal vulnerability to death, and how personal commitment to and protective 
disengagement from patient and family may be balanced.  
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Figure 4 illustrates how a patient illness trajectory (wavy arrow) moves through 
changes in the EOL care treatment aim, from a curative/preventive, to a 
curative/supportive, to a specific palliative, to an unmedicalized palliative care one. 
On the y-axis is objectively worsening patient condition as measured by function and 
symptoms toward death. 
On the x-axis are two subjective measures related to the perception of distance to 
death: deteriorating prognosis, as subjectively assessed by the doctor; and the degree 
of preparedness for death of patient, family, or the doctor/staff/carer. The figure 
implies that both the prognosis but also the degree of preparedness of patient, family, 
and doctor has implications for the treatment aim. The less prepared for death either 
the patient, family, or doctor is, the more difficult it will be to move the care goal in a 
palliative direction.  
Preparedness has been studied with respect to informal caregivers such as family, 
(242) and somewhat less with respect to health care providers. (262-264) I propose 
that preparedness for death is a suitable guiding concept as the aim for all three 
mentioned lines of care strategy: interventional strategy, relational strategy with 
patient and family, and focus of self-awareness. Preparedness at the level of medical 
intervention implies making timely adjustments to medications, aided by prognostic 
tools, discontinuing irrelevant treatment, and providing anticipatory symptom control 
therapy as-needed, ideally avoiding last-minute changes to treatment. Preparedness at 
the level of patient and family communication implies achieving agreement between 
patient, family and staff regarding the goals of care, through an integrated process of 
considerate treatment negotiations, and helping patient and family in their readiness 
for death. And when nothing else can be done or said, acknowledge this in peaceful 
presence. Preparedness at a personal level means self-awareness, practicing toward an 
“open awareness” and “courageous acceptance of death”, such as what Kissane 




Paper I adds to knowledge on EOL prescribing practices in nursing homes: 
 Palliative EOL drugs were commonly prescribed for nursing home patients 
during the last days of life.  
 Drug therapy changes were particularly common on the day of death.   
 A diagnosis of cancer and length of stay were associated with palliative EOL 
drug therapy on the day of death.  
Paper II adds to knowledge concerning the effectiveness and safety of drug therapy for 
symptomatic relief in the dying: 
 Evidence still does not support the standard use of anticholinergic drugs in the 
treatment of death rattle.  
 Some evidence supports the use of morphine and midazolam for dyspnea, 
anxiety, or terminal restlessness.  
 Limited evidence guides the choice of opioids for pain.  
Paper III adds to the understanding of nursing home doctors’ experiences in EOL care 
and how existential vulnerability impacts their work in EOL care. Feeling at times 
powerless before the palliative and communicative challenges surrounding death, 
doctors balance both personal commitment with protective distance, as well as 
treatment compromises with their sense of professional conduct, in an arduous, 
integrated process of decision-making and grief work. 
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7. Implications for practice and research 
Abundant drug therapy changes on the day of death point to a potential for better 
preparations for death in the nursing home. Characteristics of the nursing home setting 
and of the patient group challenge prognostication of dying. The doctor has a 
responsibility to promote preparedness for death both in patient, family and in 
himself/herself. Care may improve when there is time to get to know the patient and 
family.  
The lack of evidence of palliative drug treatment in the dying questions doctors’ 
ability to effectively and safely alleviate symptoms in a population that may respond 
differently to all drug treatments, and yet where patients and family are often reassured 
with the argument that this can be done. Left with few evidence based options of 
intervention in the last days and hours of life, efforts to communicate with and prepare 
patient and family for the likely symptoms of the dying phase become increasingly 
important. Researchers are particularly urged to include patients with non-malignant 
disease in clinical trials, and to conduct further high quality clinical trials on pain 
treatment in the dying. 
Existential vulnerability plays an important role in understanding EOL care 
communication and in furthering professional self-care and reflection. Professional 
conduct in EOL care needs to take into consideration both the doctor's vulnerability as 
well as that of the patient and next-of-kin. EOL care training for nursing home doctors 
may benefit from including systematic self-reflective practice, in particular addressing 
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 Abstract 
 Objective. To examine drug treatment in nursing home patients at the end of life, and identify predictors of palliative drug 
therapy.  Design. A historical cohort study.  Setting. Three urban nursing homes in Norway.  Subjects. All patients admitted 
from January 2008 and deceased before February 2013.  Main outcome measures. Drug prescriptions, diagnoses, and demo-
graphic data were collected from electronic patient records. Palliative end-of-life drug treatment was defi ned on the basis 
of indication, drug, and formulation.  Results. 524 patients were included, median (range) age at death 86 (19 – 104) years, 
59% women. On the day of death, 99.4% of the study population had active prescriptions; 74.2% had palliative drugs 
either alone (26.9%) or concomitantly with curative/preventive drugs (47.3%). Palliative drugs were associated with nurs-
ing home, length of stay    16 months (AOR 2.10, 95% CI 1.12 – 3.94), age (1.03, 1.005 – 1.05), and a diagnosis of cancer 
(2.12, 1.19 – 3.76). Most initiations of palliative drugs and withdrawals of curative/preventive drugs took place on the day 
of death.  Conclusion. Palliative drug therapy and drug therapy changes are common for nursing home patients on the last 
day of life. Improvements in end-of-life care in nursing homes imply addressing prognostication and earlier response to 
palliative needs. 
 Key Words:  Drug therapy ,  end of life care ,  general practice ,  Norway ,  nursing homes ,  palliation 
more heterogeneous NH populations is lacking. 
Derived from international and Norwegian guide-
lines [6 – 8], a shorter drug list has been recommended 
for use in NHs in Norway, comprising parenteral 
morphine, benzodiazepines, anticholinergics, and 
antipsychotics [2,5]. Previous studies on EOL care 
in NHs have reported on treatment with selected 
drug groups such as opioids and pulmonary agents 
[9], and pain relief [4] without a clearly defi ned 
palliative drug treatment. 
 Pharmacological treatment for dying patients is 
thus an important aspect of EOL care in NHs, of 
which we have little knowledge. Insight into initiation 
and discontinuation of drug therapy in this phase 
may shed light on the quality of EOL care and point 
to vulnerable patient groups. Our study aimed to 
examine drug treatment in NH patients at the EOL, 
and to identify predictors of a clearly defi ned palliative 
drug therapy. 
 Introduction 
 In Norway, 47.5% of deaths occur in nursing homes 
(NHs), 32.5% in hospitals, and 14.5% at home [1]. 
About 95% of patients in long-term care will die in 
the institution [2]. NH patients are prescribed a 
wider range of medications than any other subpopu-
lation [3,4]. For the dying patient, standing drug 
treatments must be reconsidered and often discon-
tinued. The last days of life are often characterized 
by symptoms such as pain, respiratory distress, and 
anxiety, as well as inability to take oral medications 
[5]. These symptoms may be palliated by parenterally 
administered drugs [6]. 
 Whereas palliative literature has a main focus on 
specialized care for patients with cancer in hospice 
and hospital, including a range of drug therapy 
options for the dying [6 – 8], international consensus 
on palliative end-of-life (EOL) drug treatment for 
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 Material and methods 
 Study population 
 NHs in Norway accommodate around 41 000 beds, 
corresponding to 18% of the general population 
80 years and older. All NHs provide EOL care, but 
only 42 institutions have specialized palliative care 
units. Most NH physicians in Norway are part-time 
engaged general practitioners [1]. The study popula-
tion comprised all patients in three urban NHs in 
Norway admitted from January 2008 and deceased 
before February 2013. The institutions were selected 
on the basis of using an electronic patient record 
system optimized for data extraction [10]. 
 Data collection 
 We collected routinely registered data from the 
patients ’ fi nal NH stay: demographic data (age, 
gender, date of NH admission and death, long- or 
short-term stay); diagnoses (ICD-10) [11]; medica-
tions (generic name, Anatomical Therapeutic Chem-
ical (ATC) code [12], drug formulation, regular or 
as-needed schedule, indication, dates of initiation, 
alteration, or discontinuation). An external IT con-
sultant extracted the data, and replaced ID-numbers 
with a running number, the key to which remained 
undisclosed to the research group. 
 Drug therapy 
 We defi ned palliative EOL drug therapy in NHs on 
the basis of indication, drug, and formulation; (1) 
any drug prescription with an explicit EOL care 
indication key word was included: palliative, termi-
nal, death, death rattle, Liverpool Care Pathway, or 
EOL; (2) we also included prescriptions of specifi -
cally recommended  injectable palliative EOL drugs 
for use in NHs [2,5], regardless of missing EOL key 
words in the indication text (Table I).  “ Curative/
preventive drug therapy ” , in contrast, was defi ned as 
medication for regular use without an explicit EOL 
care indication. 
 Statistical analysis 
 User rates were established for drugs according to 
the above categories. We explored predictors of pal-
liative EOL drug therapy by a chi-squared test, and 
subsequently by binary logistic regression analysis; 
dependent variable: palliative EOL drug therapy; 
independent variables: age, gender, length of stay, 
nursing home, diagnosis of cancer. All variables but 
age were analysed as categorical. Signifi cance was 
determined at a level of 5%. IBM SPSS Statistics 20 
(SPSS Inc., Chicago, Ill., USA) was used for statistical 
analyses. 
 Results 
 Patient characteristics 
 The study population comprised 524 deceased 
patients. Median (range) age at death was 86 
(19 – 104) years, 59.4% were women, 68.1% in long-
term care. The most common registered diagnoses 
were dementia (36.8% of the patients), congestive 
heart failure (29.6%), and cancer (23.7%) (Table II). 
 The three NH populations did not differ with 
regard to gender or number of diagnoses. Compared 
with the other NHs, more patients at NH C were 
86 years and older, or had a diagnosis of infection or 
cancer, p    0.01. Patients at NH A had longer stays 
 End-of-life care guidelines are centred on 
cancer patients, while nursing home patients 
die from various illnesses. 
 This study shows that palliative drugs were  •
commonly prescribed for nursing home 
patients during the last days of life. 
 A diagnosis of cancer and length of stay were  •
associated with palliative drug therapy. 
 Most initiations of palliative drugs, and most  •
withdrawals of curative/preventive drug 
therapy, occurred on the day of death. 
 Table I. Injectable drugs recommended for palliative treatment for the dying in NHs in 
Norway [2,5], by proportion (%) of users on the day of death. 
Drug name ATC code Common EOL use Proportion (%) of patients
Morphine N02AA01 Pain or dyspnoea 71.4
Glycopyrronium A03AB02 Death rattle 46.9
Scopolamine N05CM05 Death rattle 25.8
Morphine-scopolamine N02AG01 Pain or dyspnoea and death rattle 12.2
Midazolam N05CD08 Anxiety, agitation 55.0
Diazepam N05BA01 Anxiety, agitation 1.0
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(p    0.01), as the EPR data were collected from was 
used only in the long-term ward. 
 Patients with cancer more frequently died within 
two weeks of admission than patients without cancer 
(41.1% vs. 20.5%, p    0.01). Patients with dementia 
more frequently died after stays of longer than 
16 months compared with patients without this diag-
nosis (40.4% vs. 16.0%, p    0.01). 
 Drug use on the day of death 
 On the day of death, 99.4% of the study population 
were on drug therapy. The most common regular and 
as-needed drugs are shown in Table III. 
 Of the 4736 standing prescriptions (regular and 
as-needed drugs) on the day of death, palliative 
EOL drugs comprised 1306 (27.6%) and curative/
preventive drugs 2419 (51.1%), while 1011 (21.3%) 
prescriptions were not classifi ed in either category. 
Indication was documented for 99.6% of all drugs 
on the day of death. 
 Altogether 50.2% of patients were prescribed any 
drug with a specifi ed EOL care indication. The most 
common palliative EOL drugs were morphine 
(71.4% of patients), midazolam (55.0%), glycopyr-
ronium (46.9%), and haloperidol (46.9%) (see 
Table I). Palliative EOL drugs were prescribed to 
74.2% of the study population, either alone (26.9%) 
or concomitantly with curative/preventive drugs 
(47.3%). Curative/preventive drugs were prescribed 
to 72.5% of patients (alone 25.2%). Some 95.7% of 
palliative EOL drugs were prescribed as needed. 
Patients had standing prescriptions of median (25th –
 75th percentile) three (zero – eight) palliative EOL 
drugs and three (zero – four) curative/preventive 
drugs on the date of death. There was a median 
period of two (zero – seven) days from prescription to 
death for palliative EOL drugs. 
 Having prescriptions of palliative EOL drugs at 
death was associated with length of stay    16 months 
(AOR 2.10, 95% CI 1.13 – 3.95), cancer (2.12, 1.19 –
 3.76), age (1.03, 1.005 – 1.05), and being at NH B 
(3.53, 1.99 – 6.25) or NH C (4.20, 2.36 – 7.48) 
(Table IV). 
 Figure 1 shows that the proportion of patients for 
whom at least one palliative EOL drug was initiated, 
or at least one curative/preventive drug was discon-
tinued, increased in the last week before death and 
peaked on the day of death. 
 Table II. Patient characteristics (n    524). 
Median (range) age at death, years 86 (19 – 104)
Women, % 59.4
Median (range) length of stay, days 103 (0 – 1765)
Long-term care, % 68.1
Diagnoses:
Dementia, % 36.8
Congestive heart failure, % 29.6
Cancer, % 23.7
Chronic pulmonary disease, % 18.5
Infections, % 20.0
Hip fracture, % 9.7










A06A Laxatives 32.6 N02A Opioid analgesics 82.6
N02A Opioid analgesics 32.4 N05C Hypnotics 70.4
N02B Non-opioid analgesics and 
antipyretics
28.2 N05A Antipsychotics 51.1
C03C High-ceiling diuretics 26.7 N05B Anxiolytics 30.9
B01A Antithrombotic agents 24.0 N02B Non-opioid analgesics and antipyretics 26.0
N06A Antidepressants 19.1 A03A Drugs for functional gastrointestinal 
disorders 1 
24.6
C07A Beta-blocking agents 17.6 C03C High-ceiling diuretics 16.8
A02B Drugs for peptic ulcer and 
gastro-oesophageal refl ux 
disease
15.1 A03F Metoclopramide 13.4
B03B Vitamin B12 and folic acid 14.3 A06A Laxatives 13.0
N05C Hypnotics 13.5 C01D Vasodilators used in cardiac diseases 11.1
N05A Antipsychotics 11.5 R03A Adrenergic inhalants 6.3
N05B Anxiolytics 11.1 A10A Insulins and analogues 5.2
C09A ACE inhibitors, plain 8.6 B05B i.v. solutions 4.8
H02A Corticosteroids for systemic 
use, plain
8.4 R05C Expectorants, excl. combinations with 
cough suppressants
4.6
R03A Adrenergic inhalants 8.4 R03B Other drugs for obstructive airways 
disease, inhalants
4.4
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 Discussion 
 Our study shows that palliative EOL drugs were 
commonly prescribed for NH patients during the last 
days of life. NH, a diagnosis of cancer, and long stay 
were associated with palliative EOL drug therapy. 
Most initiations of palliative EOL drugs, and most 
withdrawals of curative/preventive drug therapy, 
occurred on the day of death. 
 Strengths and weaknesses 
 The study population comprised patients from all 
types of wards, and although the diagnostic data are 
not validated this broad diversity is expected to refl ect 
NH populations in general. 
 With the exception of short-term care patients 
from NH A, all patients admitted and deceased in 
three NHs during the fi ve-year study period were 
included, limiting selection bias. Only three institu-
tions participated in the study, limiting statistical 
power and to some extent generalizability. 
 A complete set of medication data for all patients 
was collected. The electronic patient record did not 
include information on whether prescribed medica-
tion was actually taken, leading to possible overesti-
mation of drug use. Prescribed medication, on the 
 Table IV. Associations between palliative EOL drug therapy and patient characteristics. 
Proportion of patients 
(%) prescribed 
palliative drugs Chi-square, p AOR 95% CI
Nursing home:
A 52.7    0.01 1 Ref
B 78.7 3.53 1.91 – 6.00
C 80.4 4.20 2.26 – 7.08
Length of stay (quartiles):
   2 weeks 81.2 0.01 1.86 0.97 – 3.25
2 weeks – 3 months 65.1 1 Ref
3 – 16 months 71.8 1.70 0.97 – 3.17
   16 months 78.6 2.10 1.13 – 3.95
Gender:
Women 75.8 0.31 1 Ref
Men 71.8 0.98 0.60 – 1.44
Age:
86  77.4 0.06 1.03 1.005 – 1.05
   86 70.0
No. of diagnoses:
  6 76.6 0.21 Variable not included
   6 71.7
Cancer:
No 71.5 0.01 1 Ref
Yes 83.1 2.12 1.30 – 4.13
Dementia:
No 72.2 0.16 1 Ref
Yes 77.7 1.43 0.88 – 2.25
Infections:
No 75.4 0.22 Variable not included
Yes 69.5
Chronic pulmonary disease:
No 75.2 0.30 Variable not included
Yes 70.1
Heart failure:
No 73.4 0.52 Variable not included
Yes 76.1
Hip fracture:
No 74.6 0.53 Variable not included
Yes 70.6
 Notes: Logistic regression model: chi-squared (8, 524)    58.41, p    0.001, Cox  & Snell R2    0.11, 
74.4% correctly classifi ed. The logistic regression was performed as a block analysis, each variable being 
adjusted by the effects of the others. Association strength is given as adjusted odds ratios (AORs), with 
95% confi dence intervals (CI). Only variables with a p    0.20 in the chi-squared test were included in 
the regression analysis, with the exception of gender which was included on the basis of being a common 
confounder. In the regression model, age was analysed as a continuous variable, all other included 
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other hand, may refl ect the doctor ’ s treatment deci-
sions more appropriately than given medication. This 
point is particularly important for palliative drugs, 
which comprised almost exclusively as-needed drug 
prescriptions. 
 Use of indication text secured a comprehensive 
defi nition of palliative EOL drugs, while inclusion of 
specifi cally recommended palliative EOL drugs 
ensured that these prescriptions were not missed 
regardless of missing EOL key words in the indica-
tion text. Restricting the latter to injectables, we 
excluded prescriptions less specifi c to the dying 
patient, such as opioid tablets, oral suspensions, and 
patches. Injectable antipsychotics and benzodia-
zepines may on occasion be used to treat neuropsy-
chiatric symptoms in dementia. A median of two 
days from prescription to death makes it less likely, 
though, that these prescriptions were issued for their 
non-palliative indications. Although anticholinergics 
have other indications, in injectable form, glycopyr-
ronium and scopolamine are seldom used for non-
palliative purposes in NHs. 
 Comparison with other studies 
 There are few other studies reporting on drug ther-
apy at the EOL in the general NH population, and 
with considerably smaller sample sizes. Decreased 
overall treatment intensity has been found in patients 
perceived as dying, across NH, hospital, and general 
practice settings in the Netherlands [13]. Patients 
with dementia dying in American NHs were pre-
scribed unchanged total numbers of drugs, palliative 
medications replacing other medications [9]. 
 Our study adds to previous knowledge showing 
that NH patients with the longest duration of stay, 
or a diagnosis of cancer, were more likely to receive 
palliative EOL drugs on the day of death than those 
without these characteristics. More than 80% of long-
term care patients have dementia [14], interfering 
with the communication of suffering, analgesia, and 
EOL care [15 – 17]. Accurate survival prediction for 
patients with advanced dementia is diffi cult, and 
may hinder palliative care [18]. Longer NH stays may 
nevertheless allow time for advance care planning 
and staff familiarity with the patient, thus facilitating 
palliation, and perhaps explaining the association 
found with the longest stays. Patients with cancer 
often have expected deaths with a typically rapid 
functional decline, and are at the centre of palliative 
guidelines [7,19]. Palliative drug therapy for this 
group was therefore expected. A diagnosis of demen-
tia, heart failure, chronic pulmonary disease, infec-
tion, or hip fracture was not associated with initiation 
of palliative drugs. This may indicate death coming 
unexpectedly. For respiratory distress in chronic pul-
monary disease there may also be a reservation among 
physicians to prescribe morphine and benzodia-
zepines, as they inhibit respiration. 
 An evidence base for EOL care in non-malignant 
conditions, which are prevalent in the general NH 
population, is scarce [20]. We found a high treatment 
rate with palliative drugs (73.9% overall, 71.9% for 
morphine), in line with 77% of NH patients with 
advanced dementia in the Netherlands receiving opi-
oids. Despite extensive prescribing, the Dutch study 
found that symptoms of pain, shortness of breath, 
and agitation were prevalent, suggesting that a pre-
scribed drug is no guarantee of satisfactory symptom 
control [21]. For this, factors such as close symptom 
assessment as well as appropriate drug dosage and 
administration are required. 
 Palliative drug therapy increased and curative/
preventive drug treatment decreased in the last week 
of life, most changes taking place on the day of death. 
A recent study in long-term care facilities in Canada 
found that care only changed substantially to pallia-
tive in nature during the last hours or days of life, 
calling for earlier awareness of impending death [22]. 
Initiation of palliative drugs is not to be expected for 
all dying patients, nor does it depend only on staff 
competence. Less palliative drug therapy could also 
come from less need for it, by having a shorter ter-
minal phase, or less burdensome symptoms. Little is 
known about the identifi cation and duration of the 
dying phase in NH patients and for how many it lasts 
long enough to allow for pharmacological response. 
Distinct death trajectories have been described for 
patients with different diseases [23], and timing of 
palliative care for patients with non-malignant diag-
noses has been shown to be particularly challenging 
[24]. Yet, relatively accurate prediction of survival for 
these patients in NHs has been shown to be feasible, 
though only in the last seven days of life [25]. 
 NH A had a lower proportion of patients pre-





























 Figure 1. Proportion of patients (%) for whom at least one 
palliative EOL drug was initiated, or at least one curative/preventive 







































192 K. Jansen et al. 
in prescribing culture between doctors may be one 
explanation. For the present study we did not collect 
this variable. 
 Meaning of the study 
 Palliative drug prescriptions and drug therapy 
changes are common for NH patients on the last day 
of life. Extensive curative/preventive drug therapy 
and comprehensive changes in drug treatment on the 
day of death may both point to the known prognos-
tication diffi culties in the multimorbidity character-
izing NH populations. Improvements of EOL care in 
NHs must address prognostication and an early 
response to palliative needs. 
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Context. Dying patients commonly experience potentially distressing symptoms. Palliative 
care guidelines recommend opioids, anticholinergics, antipsychotics and benzodiazepines for 
symptom relief.  
 
Objectives. To systematically review the effectiveness and safety of palliative drug treatment 
in the last days of life of adult patients, focusing on the management of pain, dyspnea, 
anxiety, restlessness, and death rattle. 
 
Methods. A systematic search of the literature published before December 2016 in 
PubMed/MEDLINE, Embase, CINAHL, PsycINFO, Cochrane, ClinicalTrials.gov, and 
SveMed+. Studies on safety or effectiveness of drug therapy in dying adults with at least one 
outcome on symptom control, adverse effects, or survival were included. Data for included 
studies were extracted. Study quality was assessed using the Effective Public Health Practice 
Quality assessment tool for quantitative studies. 
 
Results. Of 5940 unique titles identified, 12 studies met the inclusion criteria. Five studies 
assessed anticholinergics for death rattle, providing no evidence that scopolamine 
hydrobromide and atropine were superior to placebo. Five studies examined drugs for 
dyspnea, anxiety, or terminal restlessness, providing some evidence supporting the use of 
morphine and midazolam. Two studies examined opioids for pain, providing some support for 
morphine, diamorphine and fentanyl. Eight studies included safety outcomes, revealing no 
important differences in adverse effects between the interventions, and no evidence for 
midazolam shortening survival.  
 
Conclusion. There is a lack of evidence concerning the effectiveness and safety of palliative 
drug treatment in dying patients, and the reviewed evidence provides limited guidance for 
clinicians to assist in a distinct and significant phase of life. 
 
Key Words 
Palliative, dying, drug therapy, symptom relief, effectiveness, safety 
 
Running Title: Drug safety and effectiveness in the dying 
INTRODUCTION  
Dying patients, in the last hours and days of life, commonly experience pain, dyspnea 
(breathlessness), anxiety, restlessness, and death rattle (noisy respiratory secretions in the 
dying). (1-3) Patients at this stage are often referred to as “actively dying”, with a clinical 
presentation of waning physiologic functions converging across diagnoses. (4) Drug therapy, 
such as opioids for pain and dyspnea, anticholinergics for death rattle, antipsychotics for 
agitated delirium, and benzodiazepines for anxiety, is recommended in palliative care 
guidelines internationally. (5-13) 
The dying patient is affected by a state of physiological multi-organ failure, which in a 
number of ways may impact the effectiveness and adverse effects of drug therapy. (14) 
Patients may additionally be unable to self-report symptoms or participate in treatment 
decisions due to reduced consciousness, and proxy assessments based on observations of 
physical and behavioral factors may diverge from patient experience. (15) Lastly, palliative 
drug therapy for dying patients should neither prolong suffering nor shorten life. (16)  
The effectiveness and safety of drug therapy used for palliation in the dying patient have been 
most extensively studied in patients with terminal cancer. Extrapolation of data from 
populations with cancer to other populations has a number of issues. Most patients die from 
conditions other than cancer. (17) The illness trajectory may be more unpredictable in non-
malignant conditions, (18) with unique patterns of distress (19) affecting prognostication (20) 
and treatment. (21) Adding complexity to this, the choice to use palliative drug therapy is not 
only a purely medical decision, but typically subject to shared decision-making (22) under the 
influence of interpersonal, psychological, organizational and cultural factors. For example, 
initiation of drug treatment at the end of life is affected by negotiations with the patient’s 
family, and the physician’s own existential encounter with death. (23) Dialogue between 
doctor, staff, patient and family in order to adjust aims of treatment and care and to support 
shared decision-making is known as Advance Care Planning (ACP), (24, 25) a process which 
may or may not result in written directives specifically instructing treatment, often referred to 
as ”advance directives”, (26) “living wills” or “physician/medical treatment orders”. (27) 
The 2015 NICE guidelines on Care of dying adults in the last days of life (5) reviewed 
comparative studies on symptomatic drug treatment in the last 14 days of life. The NICE 
guidelines report one study on drug treatment of pain, three studies on breathlessness, three 
studies on nausea, and eight studies on respiratory tract secretions. However, for the treatment 
of other common symptoms in dying persons, such as anxiety, delirium or agitation no 
evidence is provided in the NICE guidelines or in two earlier Cochrane reviews on a broader 
palliative care population. (28, 29)  
This study aims to systematically review the effectiveness and safety of palliative drug 
treatment in the last days of life of adult patients, focusing on the management of pain, 
dyspnea, anxiety, restlessness, nausea and death rattle.  
 
METHODS 
This study was registered in the PROSPERO International prospective register of systematic 
reviews (CRD42016029236) and conducted in accordance with the PRISMA guidelines (see 
Appendix 1 for the PRISMA checklist).  
Search strategy 
We conducted a systematic search in PubMed/MEDLINE, Embase, CINAHL, PsycINFO, 
Cochrane, ClinicalTrials.gov, and SveMed+. The search strategy (see Appendix 2 for the 
Search strategy) was adapted from a strategy presented in the 2015 NICE Guidelines Care of 
the dying adult (A.2.1 Recognising dying). (5)  In addition, we hand-searched the reference 
lists of all included articles and relevant literature reviews.  
Inclusion/exclusion criteria 
Studies were included in the review if they used an experimental or quasi-experimental design 
(clinical trial, cohort, or case-control) to examine the effectiveness or safety of palliative drug 
therapy in adults (≥18 years) in their last two weeks of life or clinically considered dying. All 
settings, countries and diagnoses were included. Any comparison groups, or the lack of, were 
accepted. Qualitative studies, case reports, cross-sectional studies, opinion pieces and 
conference abstracts were excluded. We did not restrict our search by publication date, as we 
anticipated few high-quality studies. Studies were restricted to English, Spanish, German, 
French, Norwegian, Swedish, Danish, and Dutch languages, for the authors to be able to 
assess them. Studies that did not focus on the specified primary or secondary outcomes of 
interest listed below were excluded. 
Outcomes of interest  
• Primary outcomes: symptom or symptom control measures regarding pain, dyspnea, anxiety, 
restlessness, and death rattle; number or degree of adverse effects; and mortality or survival.  
• Secondary outcomes: level of consciousness, functional level, quality of life, and quality of care. 
Study selection and data extraction 
After removal of all duplicates, studies were evaluated in a stepwise procedure for inclusion 
in the review (Figure 1). All titles identified in the search were screened for eligibility. For 
those titles considered potentially eligible, the abstracts were screened independently by two 
authors (KJ and LP), using the inclusion criteria specified above. The full text of all articles 
meeting these criteria was assessed independently by pairs of authors (KJ and DFH, KJ and 
LP, or KJ and SR). For the 12 articles meeting the inclusion criteria, data extraction was 
performed using the McMaster Critical Review Form for quantitative studies. (30) Additional 
information on health care setting, time before death studied, diagnostic category, drug 
category, and drug administration route was also extracted. To test the study selection and 
data extraction processes, a pilot assessment and data extraction were made by all authors on 
five studies. Discrepancies were resolved via discussion between author pairs until agreement, 
or referred to at least one other review author for consensus.  
Quality assessment 
The quality of the 12 studies included in the review was assessed using the Effective Public 
Health Practice (EPHPP) Quality assessment tool for quantitative studies. (31) This tool was 
chosen for its applicability across a wide range of quantitative study designs. Studies were 
rated weak, moderate or strong on the following six components: selection bias, study design, 
confounders, blinding, data collection, and withdrawal. The quality ratings across the six 
domains were aggregated to give a global rating for each study as follows: weak (two or more 
component weak ratings), moderate (one weak rating), or strong (no weak ratings). Quality 
assessments were scored independently by three authors (KJ, DFH, and SR), and 
discrepancies discussed until consensus was reached. Bias was further discussed at an 
outcome level where considered relevant. 
 
RESULTS 
Final search date was the 21st of December 2016. Our search identified 5923 records. After 
removal of 1720 duplicates, we screened 4203 unique titles, and 819 potentially relevant 
abstracts, yielding 70 records that met the inclusion criteria. Following full-text assessment of 
these, 9 articles were included for data extraction. Hand searching the reference lists of the 
included studies as well as those of 18 systematic reviews and five review articles identified 
in the initial search, we identified three additional studies, (32-34) for a total of 12 studies 
(Figure 1). Heterogeneity of studies did not allow for meta-analysis.  
Study characteristics 
The 12 studies included for data extraction were published between 1977 and 2016 (Table 1). 
Eight studies were performed in Europe, (32-39) two in North America, (40, 41) one in Asia 
(42) and one in South America. (43) Seven studies were randomized controlled trials (RCTs), 
(32-36, 40, 43) four were prospective cohort studies (37, 38, 41, 42) and one a retrospective 
cohort study. (39) Eight studies were set in palliative care units or hospices; (34-41) with one 
of these also including home care patients. (41) The remaining four studies were set at non-
specialist palliative care hospital wards. (32, 33, 42, 43) All studies were either exclusively or 
predominantly conducted in patients with a main diagnosis of cancer. The time before death 
studied was, in all studies except one where it was not reported, (40) either expressed in terms 
of time from study entry to death, or as a life expectancy estimate (Table 1).  
The studies included a range of different palliative drug treatments. Five studies investigated 
anticholinergics, (32, 35-37, 40) five studies opioids, (33, 34, 39, 42, 43) three studies 
benzodiazepines, (33, 38, 43) and one study investigated an antipsychotic; (41) seven of the 
studies evaluated more than one drug. (33-37, 39, 43) Five studies looked at death rattle, (32, 
35-37, 40) five studies at dyspnea, (33, 38, 41-43) and two studies looked at pain. (34, 39) 
Three of the studies on dyspnea also investigated restlessness, (41) delirium (38) or anxiety. 
(43) Overall, seven included studies reported on adverse effects, (33-36, 40, 42, 43) and three 
studies reported comparatively on survival. (33, 36, 38) Data on all primary outcomes 
(symptom control, adverse effects, and survival) were identified. The only secondary outcome 
discussed in the included studies was level of consciousness. No data on impact of palliative 
drug therapy on functional level, quality of life or quality of care were identified. 
Quality assessment 
The EPHPP global rating scores for the quality of the included articles are presented in Table 
2. Two articles were rated as “strong”, seven articles were rated “moderate”, and three articles 
were rated “weak”. The most common weak component ratings were for confounders, (33, 
39, 41, 42) data collection, (39, 41, 43) blinding, (36, 38, 42) and withdrawal. (34, 35, 42)  
 
Death rattle 
 Study characteristics. Five studies examined the effectiveness of anticholinergics for 
death rattle (Table 3). The drugs studied were scopolamine butylbromide, scopolamine 
hydrobromide, glycopyrronium hydrobromide, and atropine. Four studies were RCTs, (32, 35, 
36, 40) two of which were placebo-controlled, (32, 40) and one of which was a pilot RCT; 
(35) one study had a prospective cohort design. (37) Study quality was assessed as strong in 
two studies, (37, 40) and moderate in three. (32, 35, 36) Three studies (36, 37, 40) used a 
scoring scale as proposed by Back et al. (37) to assess the severity of death rattle (0, 
inaudible; 1, audible only very close to the patient; 2, clearly audible at the end of the bed, in 
a quiet room; 3, clearly audible at about 20 ft (9.5 m), in a quiet room).  
Comparison with placebo. No drugs tested against placebo (scopolamine 
hydrobromide and atropine) were found to be superior to placebo. A placebo-controlled RCT 
from the USA comparing sublingual atropine to sublingual saline in 160 patients found no 
difference in noise score and heart rate at baseline, after 2 hours (p=0.73) and 4 hours 
(p=0.21). (40) A smaller placebo-controlled study from Germany compared intravenous (i.v.) 
or subcutaneous (s.c.) scopolamine hydrobromide to saline in 31 patients, and likewise found 
no significant difference in death rattle scores (p value not reported). (32)  
Comparison between drugs. Three head to head studies compared the effectiveness of 
different anticholinergics, with conflicting evidence regarding comparative effectiveness. A 
small double-blinded pilot RCT from Germany (n=13) comparing the effect of i.v. 
scopolamine hydrobromide and glycopyrronium found significantly less death rattle with 
glycopyrronium. (35) No difference in restlessness and expressions of pain was found 
between the two groups. Neither of the two German studies were powered to show a 
difference between groups, and results were presented as figures, with no percentages shown. 
(32, 35) An RCT from Belgium (n=333) revealed that s.c. atropine, scopolamine 
butylbromide and scopolamine hydrobromide reduced noise score in around 40% of cases, 
with no significant difference between the drugs. (36) In considering this outcome, it should 
be noted that the study was not blinded, and there was no systematic recording of intravenous 
and oral fluid intake, which could have influenced the development of the death rattle. A 
prospective cohort study from the UK (n=170) revealed significantly more patients with 
reduced death rattle noise scores 30 minutes after injection of scopolamine butylbromide 
(p=0.002), and less need for a second injection (p=0.03) compared with glycopyrronium. (37) 
The dose of glycopyrronium was not quite equipotent (0.20 mg given, 0.27 mg needed) to the 
scopolamine butylbromide dose, possibly influencing the findings. No important differences 
in adverse effects or survival were noted in the studies, although the Belgian study noted a 
temporarily decreased consciousness with scopolamine hydrobromide compared to atropine 
and scopolamine butylbromide after 12 hours (P=0.0076) but not after 24 hours.  
 
Dyspnea 
Study characteristics. Five studies investigated the effectiveness of drug therapy for 
dyspnea, either alone (33, 42) or in combination with anxiety, (43) agitated delirium (38) or 
terminal restlessness (41)Three of the studies reported also on safety outcomes (Table 2). (33, 
42 , 43) Drugs studied were the opioids morphine (33, 43) and fentanyl, (42) the 
benzodiazepine midazolam, (33, 38, 43) and the antipsychotic chlorpromazine. (41) Two 
studies were RCTs, (33, 43) and three were prospective cohort studies.  (38, 41, 42) Study 
quality was assessed as weak in two studies, (41, 42) and moderate in three. (33, 38, 43)  
Morphine and midazolam for dyspnea. Some evidence was found to support the use of 
morphine and midazolam for dyspnea. An RCT from Argentina (n=51) compared s.c. 
morphine plus midazolam (MM) versus oxygen. (43) Based on a verbal rating scale, 
significant dyspnea improvement was found in both groups, in favor of MM at 24 hours 
(p=0.03). Nausea was reported for both groups. An RCT from Italy (n=101) also found more 
patients experiencing dyspnea relief according to a modified Borg scale in the continuous s.c. 
MM group compared to the morphine (p=0.03) or midazolam (p=0.0004) alone groups after 
24 hours, a benefit which after 48 hours only stayed significantly different compared to 
midazolam alone (p=0.04). (33) Somnolence was more frequent in the morphine group. 
Navigante et al. attribute the somnolence to the frequent episodes of breakthrough dyspnea in 
this group being treated by higher doses of midazolam compared to the two other groups, in 
the form of frequent midazolam rescue doses. This study also had a high attrition rate due to 
deaths within the observation period of 48 hours (31/101). No significant difference in 
survival between the groups was noted. 
Fentanyl for dyspnea. A small uncontrolled prospective cohort study from Singapore 
(n=16) found no effectiveness of i.v. fentanyl to relieve dyspnea. (42) Based on self-reported 
dyspnea severity after 24 hours compared with severity at infusion start, no significant 
difference was found between the proportion of non-responders versus responders (56.3% vs 
43.8%, p=0.33). Few adverse effects were reported. Although five patients did not die within 
the same hospital admission, mean survival for deceased patients was 7 days. Also, 20 
patients dropped out, being too ill to self-report symptoms, or dying before 24 hours, 
rendering this a dying population for the purposes of this study.  
 
Anxiety 
Some evidence was also found to support the use of morphine and midazolam for anxiety. 
The above mentioned RCT from Argentina (n=51) compared s.c. morphine plus midazolam 
(MM) versus oxygen for anxiety. (43) An improvement in anxiety was observed for both 
groups at 20 min, but after 24 hours only in the MM group (p=0.035), MM performing better 
than oxygen both at 20 minutes (p=0.024) and 24 hours (p=0.032). 
 
Terminal restlessness 
Two studies investigated the effectiveness of drug therapy on agitated delirium or terminal 
restlessness. (38, 41) A prospective cohort study from Italy supported the use of midazolam 
for agitated delirium. (38) Continuous i.v. midazolam given as a sedation regimen in 42 
patients gave less symptoms (p=0.0001) with increasing drug doses. (38) There was no 
control group for the effect outcomes and we assessed the study quality as weak. Survival 
from admission in patients sedated with midazolam was longer compared with a control 
group that was not sedated (p=0.003), but details of the drug treatment and the condition of 
unsedated patients were not reported, and there may have been a selection bias.  
An uncontrolled prospective cohort study for the effectiveness of i.v./rectal chlorpromazine 
sedation on dyspnea (10 patients) and restlessness (10 patients) included both palliative care 
inpatients and outpatients in the USA. The study did not discriminate effectiveness results 
with respect to the two symptoms included, but reported complete symptom relief in 18/20 
patients and partial relief in 2/20 patients before death. (41) Although McIver et al. concluded 
that chlorpromazine is highly effective, the lack of control group opens for confounding, data 
collection tools lacked reliability and validity, and study size was small. 
 
Pain 
Our review includes two studies specifically investigating treatment of pain in the dying. (34, 
39) Overall, there appears to be little evidence supporting drug treatment for pain in the 
dying. Oral morphine was superior to oral diamorphine in controlling pain in male patients in 
one RCT, (34) and fentanyl patches were more effective than intravenous diamorphine in a 
retrospective cohort study. (39) However, the differences between groups were likely 
explained by confounders in both studies. In the crossover RCT on 146 patients, male patients 
had more pain (16.8 mm difference between group means as measured on a Visual Analogue 
Scale (VAS), p<0.01) and worse mood score (12.5 mm difference, p<0.01) when given 
diamorphine compared to when given morphine. (34) No difference was found for female 
patients, and results across genders were not reported. The doses of the two agents were 
according to the authors probably not equipotent, with 1.5 mg diamorphine hydrochloride 
compared to 1 mg morphine sulphate. Furthermore, there was a high attrition rate in the study 
with only 21% (n=146/699) of participants crossing over to receive a second agent. A 
retrospective cohort study comparing the effect of a fentanyl patch versus diamorphine in a 
syringe driver in 94 patients reported better pain control at 20 hours and 8 hours compared to 
the diamorphine group. In addition, the fentanyl group used fewer “as required” opioid doses 
on the last day of life (p=0.001). (39) Both groups had good pain control in the last 48 hours 
of life. Patients having fentanyl patches received approximately twice the equianalgesic dose 
of those receiving diamorphine and although patients were matched for age, sex, and 
diagnosis, fentanyl patches were considered a second-line treatment, indicating that patients 
treated with fentanyl patches may have had more complex pain. 
 
DISCUSSION 
This systematic review shows that despite routine use of palliative drug therapy for symptom 
control in dying adults, there is little evidence regarding the effectiveness and safety of the 
commonly used agents. Twelve studies examining the effectiveness (n=12) and safety (n=8) 
of palliative drug therapy across a range of symptoms were reviewed. Despite including both 
experimental and quasi-experimental designs the included studies were small scale and only 
two were considered to be of strong quality, further limiting their contribution to the evidence 
base of palliative drug therapy in dying adults. 
Death rattle 
No evidence supporting the use of anticholinergics for death rattle was found. Our review 
found that anticholinergics were no better than placebo for reducing death rattle. Similar 
findings have been previously reported in two reviews. (5, 44) Our review highlights possible 
safety concerns associated with the use of scopolamine hydrobromide when compared to 
atropine and scopolamine butylbromide, in the form of temporarily decreased consciousness. 
Death rattle is a symptom with uncertain impact on the patient, not associated with respiratory 
distress in the patient, (45) but difficult to endure for family and staff. (46, 47). In absence of 
evidence and with uncertainty regarding the need for its treatment, reassuring communication 
with next-of-kin may be preferable. (44, 48, 49) 
Dyspnea  
In this review we found some evidence regarding the use of morphine and midazolam, 
especially in combination, for management of dyspnea in dying patients. Our results support 
those previously reported in the NICE review of 2015. While we found some evidence for 
morphine/midazolam, no evidence supporting the use of fentanyl was found. A single 
prospective cohort study examining the use of i.v. fentanyl was included in the review. (42) 
No significant response to i.v. fentanyl was reported, but the uncontrolled study design may 
weaken the strength of this conclusion and further studies are needed. Looking at a broader 
palliative care population and not just the actively dying patient, two recently updated 
Cochrane reviews have found no evidence supporting the use of benzodiazepines for the relief 
of breathlessness in people with advanced cancer and chronic obstructive pulmonary disease 
(COPD), (50) and only some low-quality evidence showing benefit of oral or parenteral 
opioids to palliate breathlessness. (51)  
No major safety concerns regarding the use of morphine, midazolam or fentanyl for dyspnea 
in the dying were identified in this review. Adverse effects associated with the use of 
palliative drug therapy for dyspnea established in the broader palliative care population 
include drowsiness, nausea and vomiting with opioids, and somnolence with benzodiazepines. 
(50, 51) However, the safety of opioids for dyspnea relief is further substantiated in broader 
palliative care populations in a 2014 systematic review, finding no compromise of respiratory 
function. (52)  
Anxiety 
Our review identified one RCT from Argentina addressing the use of palliative drug therapy 
for the management of anxiety in the dying patient, finding that a combination of midazolam 
and morphine was more effective than the use of oxygen. (43) No studies meeting the 
inclusion criteria were found in the earlier NICE review, (5) nor in a Cochrane review 
updated in 2012 on drug therapy for anxiety in a broader palliative care population. (29) 
Terminal restlessness  
The present review found limited evidence supporting the use of midazolam and 
chlorpromazine for terminal restlessness, in two studies of palliative sedation. (38, 41) 
Neither study reported specifically on adverse effects, but the study by Mercadante et al. 
reported no reduced survival associated with the use of midazolam for palliative sedation.  
A review of the evidence for treatment of delirium or agitation in the dying by NICE in 2015 
(5) and a Cochrane review from 2012 (28) also found insufficient evidence to draw 
conclusions about the role of drug therapy in the treatment of delirium in terminally ill 
patients. A more recent Cochrane review from 2015 found limited evidence for the 
effectiveness of palliative sedation in terms of quality of life and symptom control, but did not 
differentiate between pharmacological agents. (53) In line with our review, the 2015 
Cochrane review concluded that palliative sedation does not hasten death, a central ethical 
concern. 
Pain  
A pain-free death is a central theme for patients, family, and health-care providers when 
defining a “good death”, (54) and pain is a common distress in the dying. (3) Our review 
identified only two studies addressing pain treatment in the dying. Morphine, diamorphine 
and fentanyl patches have been studied, but considerable confounding makes interpretation of 
the results problematic, limiting their contribution to the evidence-base. While palliative 
sedation may be indicated for refractory pain, uncontrolled pain was not an indication for 
sedation in the two studies included in this review, although concomitantly present in 4/42 
patients in one of them. (38) Opioid studies in populations who are dying are challenging. An 
analgesic effect of opioids is clearly expected, making placebo controlled groups ethically 
unjustified. However, issues of altered absorption, metabolism and elimination of opioids in 
dying patients may affect treatment effectiveness and adverse effect profiles. (14, 55) Further 
high quality clinical trials comparing pain treatments in the dying are warranted to guide 
clinical practice regarding this critical issue. 
Adverse effects and survival 
Overall, few adverse effects were reported in the articles included in the current review, and 
several studies did not report on adverse effects at all. One explanation may be that the 
distinction of therapeutic versus adverse drug effects may be unclear in the actively dying 
patient. In particular, a sedative effect may be an adverse effect when an opioid is given to 
alleviate pain, but therapeutic when midazolam is given for restlessness or anxiety. The 
relative sedative impact is also lesser if the patient’s level of consciousness is already 
decreased. In addition, although some adverse effects have obvious objective presentations 
such as injection site redness, vomiting or respiratory depression, subjective discomfort such 
as nausea may also be harder to acknowledge in a patient with decreased consciousness. 
While palliative drugs have known potentially life-shortening adverse effects, typically 
respiratory depression with the use of opioids and benzodiazepines, (56, 57) and possibly 
increased mortality with the use of antipsychotics, (58, 59) no life-shortening effect was 
reported in the studies included in our current review. One study reported a paradoxical 
prolonging of life as with opioids used for palliative sedation. (38) Similar findings have also 
been reported with opioids used for dyspnea relief (60) and palliative drug therapy for 
terminally ill patients in the intensive care unit.(61) The effect has been attributed to the relief 
from distress. (60)  
 
Strengths and limitations 
This review addresses the prevalent and relevant issue of distress in the dying. The review is 
comprehensive, including seven different databases, and employing broader inclusion criteria 
than has previously been done, including cohort design studies, and articles in seven 
languages in addition to English. We employed a rigorous data extraction and quality 
assessment procedure.  
The present review used a clear definition of dying, including individual studies either 
reporting results in the last two weeks of life, or clinically considered dying. The same cut-off 
has been used in an earlier review. (5)  
Proximity to death naturally engenders high attrition rates in prospective studies, which 
substantially limited the sample size in several of the included studies. (33, 34, 42) The facts 
that all studies except one were performed in a palliative care unit or hospital, and almost all 
patients had cancer, may also limit generalizability to other patient groups and settings. Non-
malignant conditions are more prevalent causes of death than cancer. (17, 62) While the 
relative lack of studies on these patients is representative for palliative care research in 
general, recent years has seen a shift in the focus toward including non-malignant conditions. 
(63)  
Interpreting symptom outcomes in the included studies must be done with caution for several 
reasons. The proxy judgement of distress used in many of the included studies, required in 
situations where patients lack ability to self-report, is vulnerable to misinterpretation. (15, 64, 
65) Patients with dementia, particularly common in the setting of nursing homes, (66) may 
lack the ability to self-report symptoms long before the dying phase. (67) To complicate this, 
drugs have multiple effects that treat several symptoms at the same time. In the studies 
included in this review, midazolam, a primarily sedative drug, is used for symptomatic 
treatment for several indications such as anxiety, (43) dyspnea, (33, 38, 43) terminal 
restlessness and refractory symptoms in general. (38) Overlap of symptom presentation and 
drug effects may make treatment strategies simpler, but complicate the design and 
interpretation of intervention studies in this population. These and other challenges 
considered, clinical trials in a more broadly defined end of life care population have 




This review found limited evidence regarding the safety and effectiveness of palliative drug 
therapy for the management of commonly occurring symptoms associated with dying. Current 
evidence does not support the standard use of anticholinergic drugs in the treatment of death 
rattle. Some evidence supports the use of morphine and midazolam for dyspnea, anxiety, or 
terminal restlessness. Limited evidence guides the choice of opioids for pain.     
The lack of evidence demonstrated by this review questions our ability to effectively and 
safely alleviate symptoms in a population that may respond differently to all drug treatments, 
and yet where patients and family are often reassured with the argument that this can be done. 
Left with few evidence based options of intervention in the last days and hours of life, efforts 
to communicate with and prepare patient and family for the likely symptoms of the dying 
phase become increasingly important. Researchers are particularly urged to include patients 
with non-malignant disease in clinical trials, and to conduct further high quality clinical trials 
on pain treatment in the dying.   
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A B S T R A C T
Objective: Explore the impact of existential vulnerability for nursing home doctors’ experiences with
dying patients and their families.
Methods: We conducted a qualitative study based on three focus group interviews with purposive
samples of 17 nursing home doctors. The interviews were audio-recorded, transcribed, and analyzed with
systematic text condensation.
Results: Nursing home doctors experienced having to balance treatment compromises in order to assist
patients’ and families’ preparation for death, with their sense of professional conduct. This was an
arduous process demanding patience and consideration. Existential vulnerability also manifested as
powerlessness mastering issues of life and death and families’ expectations. Standard phrases could help
convey complex messages of uncertainty and graveness. Personal commitment was balanced with
protective disengagement on the patient’s deathbed, triggering both feelings of wonder and guilt.
Conclusion: Existential vulnerability is experienced as a burden of powerlessness and guilt in difficult
treatment compromises and in the need for protective disengagement, but also as a resource in
communication and professional coping.
Practice implications: End-of-life care training for nursing home doctors should include self-reflective
practice, in particular addressing treatment compromises and professional conduct in the dialogue with
patient and next-of-kin.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Illness, loss of function, and the prospect of death make all
human beings vulnerable to existential suffering. This may include
challenges such as dependency, meaninglessness in present life,
hopelessness, burden on others, loss of social role functioning, and
feeling emotionally irrelevant [1]. Little is known about profes-
sional palliative care providers’ experiences supporting other
people in existential suffering [2]. The doctor’s vulnerability is
central in Vetlesen’s existential approach to the clinical encounter.
Acknowledging vulnerability as a basic element of humanity
common to both patient and doctor, he argues, is a precondition for
accessing the patient’s perspective [3]. Although intuitively
viewed as a weakness, the doctor’s vulnerability may be valuable
to successful patient communication [3,4]. Doctors’ own existen-
tial vulnerability facing matters of life and death has been
underestimated [5], and it is unclear how such vulnerability
should be viewed as part of a professional identity.
Kissane suggests eight types of existential challenges for
patients with advanced illness: 1) death anxiety, 2) loss and
change, 3) freedom with choice, 4) dignity of the self, 5)
fundamental aloneness, 6) altered quality of relationships, 7)
meaning, and 8) mystery [6]. To each of these, he offers a
suggestion to doctors on how to facilitate adaptive responses.
Kissane’s typology might also be useful to understand the
challenges of doctors working in EOL care, given the common
human nature of patients and doctors. However, the doctor’s
professional role is defined as a contrast to the patient role, thereby
potentially also alienating itself from the vulnerability of its
counterpart. Such an opposition may have consequences for the
experiences and expressions of existential distress, adaptive
responses, and facilitation strategies for doctors.* Corresponding author at: Research Unit for General Practice, Kalfarveien 31, N-
5018 Bergen, Norway.
E-mail address: jansen.kristian@gmail.com (K. Jansen).
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About 45% of deaths in Norway occur in nursing homes [7],
making them the most common provider of end-of-life (EOL) care
in the country. Nursing home doctors are central team-members in
EOL care responsible for treatment decisions such as initiation and
withdrawal of drug therapy, and hospital admission. These
decisions are often difficult. Nursing home doctors value a well-
functioning relationship with the nurse [8]. They also value
consensus about the patient's health status and an appropriate
care plan between staff, as well as with the patient and family [9].
They perceive themselves to provide less emotional support to
families compared to nurses and aides [10], and family members
call for their increased involvement in EOL care [11,12]. Discor-
dance between the demand from staff for medications and the
patients’ actual need of nursing care is reported, in particular when
not being able to fulfill the existential needs of the nursing home
patients [8].
As experienced nursing home doctors, GPs (KJ and SR), and a
hospital doctor (MAS) with a key interest in improving EOL care,
and studying existential conversations and interactions (KM and
MAS), we therefore set out to explore the impact of existential
vulnerability for nursing home doctors’ experiences with dying
patients and their families.
2. Methods
We conducted a qualitative study based on three focus group
interviews, each including five to six nursing home doctors,
conducted in two Norwegian municipalities.
2.1. Study context and participants
Norway spends a higher share of total health expenditures in
long-term care facilities than most countries in the world [13]. In
2014, doctors were available on average 0.49 weekly hours per
nursing home bed [14]. Nursing home doctors in Norway are a
blend of general practitioners providing a part-time service, and
increasingly, dedicated nursing home doctors commonly working
at larger nursing homes.
Participants were recruited by email correspondence, with
senior consultants in the municipalities providing contact
information. The first focus group was invited directly by email
to the nursing home doctors. In further recruitment this approach
did not prove fruitful. Local groups of nursing home doctors
meeting for Continuing Medical Education purposes therefore
provided starting points for recruitment for the last groups.
We included a purposive sample of 17 nursing home doctors
based in two Norwegian municipalities, aiming for variation in
gender (10 women, 7 men), age (33–65 years), clinical experience
(3–29 years), part-time or full-time engagement (14 versus 3), and
specialty background (3 doctors were specialists in general
practice, 3 hospital specialists, the remainder had no specialty
background). The first author knew several participants in the first
and second focus groups from earlier work as a nursing home
doctor in the same municipality. Most doctors did not declare any
particular religious background, seven doctors declared a Christian
faith, and two described themselves as agnostic.
2.2. Data collection
The moderator (KJ) asked participants to share an episode
treating seriously ill or dying nursing home patients that they
found challenging. After the first interview, in an attempt to
facilitate stories of vulnerability or challenges while also allowing
for stories of success, participants were invited to share an
experience that had made a profound impression on them. These
stories were starting points for an open exploration of participant’s
experiences, using a brief interview guide covering issues such as
prognostication, own relationship to death, and talking about
dying.
The interviews lasted for 90 min. The first author served as
moderator in all interviews, the last author as secretary taking field
notes. The first author taped and transcribed the interviews
verbatim. Data collection was closed after three focus group
interviews, as we assessed the data sufficiently rich to illuminate
the research question.
2.3. Analysis
All authors participated in the analytical process following the
steps according to Systematic Text Condensation [15] (Fig. A1) [16].
First, we read the transcripts for an overall impression, identifying
preliminary themes. Second, units of meaning were identified and
coded independently by all the authors, representing different
aspects of challenging experiences in EOL care and how these were
dealt with. Third, the content of the code groups and subgroups
was abstracted into condensates, each illustrated by a quotation.
Fourth, generalized descriptions of experiences with dying
patients associated with existential vulnerability were developed
in an iterative process. Theoretical perspectives from Kissane [6]
and Vetlesen [3,17] sharpened the interpretative focus [18] of the
final analytic stages on experiences concerning existential
vulnerability. At each step, the code groups were reflected upon
and renegotiated in the author group. A decision trail documented
the choices during the analytic process [19].
2.4. Ethics and approval
The Western Regional Committee for Medical and Health
Research Ethics (2012/1091) and Norwegian Social Science Data
Services (#31098) approved the study. Pseudonym participant
names were used in the transcription and analysis.
3. Results
Nursing home doctors experienced having to balance treatment
compromises in order to assist patients’ and families’ preparation
for death, with their sense of professional conduct. This was an
arduous process demanding patience and consideration. Existen-
tial vulnerability also manifested as powerlessness mastering
issues of life and death and families’ expectations. Standard
phrases could help convey complex messages of uncertainty and
graveness. Personal commitment was balanced with protective
disengagement on the patient's deathbed, triggering both feelings
of wonder and guilt. These findings are elaborated below. Selected
quotations have been chosen to illustrate the findings.
3.1. Doctors balance treatment compromises in order to assist patients’
and families’ preparation for death, with their sense of professional
conduct
The doctors unanimously emphasized the importance of
preparing patients and their families for death. They described
advance care dialogues, grief work and joint decision-making in
many occasions to be a slow and arduous process for all parties.
They experienced a duty to take into account the requests of next-
of-kin in decision-making, as these would later have to live with
the consequences. Doctors sensed that family members needed to
see the patient be given “a chance” to realize that the patient’s life
could not be saved. Accepting futile treatment in order to ease the
grief process for the next-of-kin could oppose the patient’s wishes
as well as the doctors’ professional standards. In such situations,
doctors felt the need for difficult compromises, revealing and
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challenging their own vulnerability. These compromises included
administering intravenous fluids, nutrition and antibiotics in
discord with the doctors’ professional and personal opinion. An
experienced doctor described how he yielded to pressure from
relatives for further treatment, in a patient with metastasized lung
cancer who did not want treatment:
«And then there came a moment when the family and his wife said:
yes, but isn’t he going to get nutrition? And at that point nutrition
wasn’t medically relevant, but just to do something good. ( . . . ) And I
did go so far, then, that I ordered intravenous nutrition. ( . . . ) I have
many times been in situations where . . . we actually have to yield
quite a lot.» (Nathan)
The participants said that it was essential to them to adopt an
attitude of patience and carefulness in these challenging processes.
They would encounter widely different patients and families, with
varying degrees of acceptance of their situation, need for
information and preparedness for death. Doctors described
treading gingerly, sometimes taking a step back, listening and
not pushing things. One doctor told about his negotiations with the
family of a seriously ill stroke patient who repeatedly pulled out his
feeding tube. It took many conversations with the whole family
before they accepted not giving the patient yet another feeding
tube. Another doctor had a similar story regarding intravenous
drips:
«What makes this so hard? I think it’s . . . We see that we can’t do
what’s best for the patient, what we think is the best for the patient,
and what the patient says that he wants. ( . . . ) And that I think is
quite a difficult ethical dilemma.» (Sarah)
3.2. Doctors’ vulnerability manifested as feelings of powerlessness
mastering life and death, and families’ expectations
Several participants described situations where they felt
powerless and uncertain in their professional role. This could be
with patients that were difficult to palliate, striving to find words
to console the patient or families, or when they could not uphold
their assurances to the patient or families. A young nursing home
doctor spoke of her meeting with an old patient with grave and
deteriorating heart failure. She was overwhelmed by the task of
both having to console both the patient and her family:
«I was unsure if she was dying, if she knew who was around her,
and if she could hear anything at all. Then I spoke to her, while her
daughter was crying, and I felt that I fell short of helping both of them. I
tried speaking to the patient, the dying woman, but didn’t know what
to say to the daughter. It was hard. I couldn’t find any comforting
words.» (Trish)
Another challenge for the doctors was to respond to patients’ or
next-of-kin’s inquiries about prognosis, reflecting an uncertainty
regarding diagnosing dying patients. They feared a «Lazarus-
effect», whereby the patient suddenly would improve after having
removed their regular medications and their families having been
informed of imminent death. To deal with this, the doctors
employed standard wording that would convey the seriousness of
the situation and at the same time the uncertainty, such as: «I have
stopped guessing», «this is no longer in our hands», or «we will let
nature take its course». They would seldom use religious allusions,
but a doctor who himself was not Christian would sometimes say
«God has a plan with us all». Even in the cases where death was
clearly near, the doctor could feel guilty of being the «bad informer»
explicitly revealing the patient her dire prognosis. An experienced
female doctor speaking to a patient with senile dementia
illustrated this vulnerability:
«And we knew he would die. And we had agreed that if he asked, I
would be the bad guy informing him, and the nurse would comfort
him. ( . . . ) But then he lay there in bed, breathing heavily, and then he
says to me, because he knew I was a doctor: ‘Out of breath’. I say: ‘Yes,
you are ill’. Then he looks at me and says: ‘is it serious?’ And I answer
‘Yes.’ And then he asks: ‘Will I die?’. And he had dementia, and it was a
little difficult to answer straight out ‘Yes’ to that. I felt. ( . . . ) I
answered: ‘Yes’, and then I had a little break, and then I said: ‘We are
all going to die’. (Mary)
3.3. Balancing personal commitment and protective disengagement
on the patient’s deathbed
Several participants expressed their own acquaintance with
death as difficult. Conversations about death at the ward were
demanding, and they would often hesitate to engage in them. They
said that the death of a patient could remind them of the
eventuality of their own parents or children falling in a similar
situation. A male doctor felt guilty about not showing as much
feeling as the nurses would after his patients had passed away,
even though he had participated in several patients’ funerals. He
interpreted this as self-protection against personal involvement,
similar to when he sometimes referred to the local vicar service
instead of himself talking with the patient about death. Several
participants experienced seemingly contradictory feelings, as they
witnessed the end of a prolonged trajectory of suffering – a feeling
of compassion could alternate with, or change into, relief:
«I remember once, to see them not have to suffer any more, for
example to see them the next day lying nicely cleaned in bed . . . There
was a sailor here who died, he had a terrible last year after a stroke,
and suddenly he lay in bed completely relaxed, with seagulls crying in
the background – because they always have seagulls and baby seagulls
here in the summer – it was incredible! There’s something about it,
that it can be good to let go, and in a way have a peace about it.»
(Elisabeth)
The doctors expressed that by daring to take off their white coat
and making themselves accessible as fellow human beings, time
spent with the dying and their relatives could feel sacred,
meaningful and rewarding. Several participants described touch-
ing encounters with patient and families. A dying patient with
dementia would in a clear moment share a dream of her deceased
husband with the doctor. The doctors described a sense of awe to
sit by the patient deathbed, holding the dying person’s hand, and
feeling a peace and calm unique to dying. They sometimes felt deep
gratitude in patients when futile treatments were abandoned, and
were happy when they managed to comfort patients by talking and
not only prescribing medications. The joy of seeing the patient as a
person and not just for their illness also gave a greater perspective
on their own lives, and an opportunity to cope better in a difficult
profession, some of them remarked. A young doctor expressed how
daring to be a buddy with an alcoholic patient with liver cancer in
his last two months had facilitated their interaction when the day
came that the patient was dying, and words were more difficult to
find.
«He was not one of those I followed for years. However, in a way it
was hard for me not being able to contribute so much. Just being
present. But on the other hand . . . with him I didn’t have to say so
much. He recognized me when I came in. And we were both at ease
with the fact that he had complaints that we could not fully palliate.
And that things were going downward. I felt that was something
positive, too.» (Gary)
4. Discussion and conclusion
4.1. Discussion
Feeling at times powerless before the palliative and communi-
cative challenges surrounding death, doctors balance both
personal commitment with protective distance, as well as
treatment compromises with their sense of professional conduct,
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in an arduous, integrated process of decision-making and grief
work. Below, we discuss strengths, limitations, and interpretations
of these findings.
4.1.1. Validity and transferability
Focus-group interviews are preferable in seeking information
on attitudes, viewpoints, and personal experiences in environ-
ments of cooperation and interaction [20,21]. Even though
exposing vulnerability of the participants could have called for
the more intimate setting of individual interviews, the group
seemed well able to admit shortcomings and share challenging
experiences, successful or not. We believe that the participants,
facilitated by group reflection, were presenting their experiences
without excessive concern about making a favorable impression.
Contributing to this may have been the fact that most of the
participants knew each other [22,23], and all including the
moderator and secretary shared the same profession, as well as
familiarity dealing with life-and-death issues. The fact that the first
author knew several of the participants in the first and second
focus groups, may also have contributed to this. However, we did
not notice any substantial difference in the ease of discussion nor
subjects raised between the groups. The purposive sample of
participants represented a rich variation in age, gender, working
experience, and nursing home institutions. Although EOL care is a
team effort, our study focused on nursing home doctors, as
compared to other staff groups or care providers. This is because
factors considered important at the end of life are known to differ
by professional role [24]. Also, we consider the voice of nursing
home doctors faint in previous literature, and their existential
vulnerability an underexposed issue.
Although we believe international comparisons to our results
are reasonable within a Western cultural setting, doctor’s
experiences are likely to be influenced by factors such as doctor
availability and EOL care competence, role of nursing home in
health care, and cultural differences in attitudes and communica-
tion. In particular, doctor availability and staff resources are likely
to allow more time for patient and family dialogue, as well as the
reflection and self-care that have been shown central to coping
with the emotional, physical, and existential demands of EOL care
[25–28]. Norway’s health expenditures in long-term care facilities
are privileged in a global perspective, comparable mainly to the
Netherlands, Switzerland, Belgium, Denmark, and Sweden [13].
The authors’ preconceptions are an integral element of
interpretation in qualitative studies. The nature of EOL care as
burdensome yet rewarding was part of the authors’ preconcep-
tions from own experience. Nursing home medicine and EOL care
have low-status in healthcare. As a nursing home doctor and
general practitioner, the first author has firsthand experience of a
complexity and sense of importance to this work that feels to
deserve otherwise. We may therefore have had a special awareness
for aspects of EOL care that are personally and professionally
challenging yet rewarding.
4.1.2. Doctors’ existential vulnerability – what does this study add?
Our study adds to existing knowledge by presenting the
concrete impact of existential vulnerability in the context of
nursing home doctors working in EOL care, such as how they
balance personal commitment with protective distance, and
professional conduct with treatment compromises. Furthermore,
our analysis adds to the understanding of nursing home doctors’
experiences in EOL care, where emotions such as powerlessness
and guilt, and strategies such as standard phrasing, are further
interpreted in an existential context below.
In Kissane’s existential typology, the perceived powerlessness
of doctors facing the dying patient may be viewed as a threat to
their need of control, and in prolongation, to their professional
freedom and autonomy [6]. Nursing home doctors positively value
freedom and autonomy [8,25]. The need to know the timing of
death nevertheless seems more important to patients and family
than doctors [29]. Standard expressions of uncertainty of progno-
sis, such as “we will let nature take its course” may help situate the
doctor on the side as an onlooker, a position that relieves their
responsibility for the ensuing course of illness. Our analysis
demonstrated how protective disengagement from the situation of
dying could be balanced by experiences of personal presence and a
sense of awe. Such a feeling of reverence for the mystery of death,
points to the spiritual significance of EOL care. The adaptive
responses of doctors here swing between peaceful presence and
guilt-laden distance, illustrating that professional conduct in this
specific context is not straightforward.
In long-term care doctors may know patients for months or
years. This could make doctors feel closer to and more easily be
vulnerable in front of their patients, or more easily be touched.
Nevertheless the story of being a devil’s advocate of an explicit
message of death that nobody wants to be associated with,
demonstrates the stigma of death, and the doctor’s instinct to
preserve dignity for herself and her patient. The doctor may fear
removing hope, adding to the burden of the patient, or making the
prognosis self-fulfilling [29]. Participants also felt guilty for not
showing feelings before the patients and their families, at the same
time needing a protective distance. A need for emotional control is
clearly not unique to doctors relating to dying patients or their
families. In view of Kissane’s perspectives, however, a need for
distancing from death and dying is also an expression of human
beings’ anxiety of death [6].
Doctors’ vulnerability may on the other hand be more linked to
their sense of responsibility than to death itself, consistent with
what has been shown in interviews with hospital doctors [5].
Sharing responsibility helped these doctors create a supporting
alliance with their patients similar to the joint decision-making
processes and compromises with patient and next-of-kin de-
scribed by our participants. Our findings support Aase Schaufel’s
idea of a “vulnerable responsibility” of nursing home doctors in
EOL care [5]. This is demonstrated by the difficult balance of
treatment negotiations with next-of-kin, and the doctors' sense of
professional conduct. The powerlessness experienced by the
doctors may in part also be viewed as a consequence of assuming
a vulnerable responsibility for the challenging, and one must
assume often unsuccessful, task of palliating existential suffering.
While there is a broad range of manualized interventions for
treating existential distress in patients [30], limited empirical
research exists on the effectiveness of these [26].
A central concern for medical professionalism is patient welfare
[31,32]. In contrast, participants told many stories of next-of-kin
centered decision-making. Next-of-kin are important proxy
responders in EOL decision-making. Many barriers have been
reported to proxy decision-making for people with dementia, and
end of life decisions are considered particularly difficult to make as
such [33]. The views of cognitively able nursing home patients and
their relatives have been reported to differ [34]. Although the
insistence of patient and family on interventions that the doctor
considers futile is not a surprise [35], treatment decisions possibly
aggravating the suffering of the dying patient raise important
questions of ethical focus and legal acceptability. Doctors would
not be vulnerable to this dilemma had they not experienced a
conflicting moral obligation of beneficence and non-maleficence
[36] toward next-of-kin.
Showing emotions and personal commitment may be com-
mensurable with professionalism to the extent that it reflects
respect for the patient and next-of-kin, and does not hamper good
judgment [32]. As exposed by Vetlesen [3] and further elaborated
in later studies [4,5], doctors in the present study express how
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compassionate engagement and revealing a shared human
vulnerability may even be desirable in strengthening the partner-
ship with patient and next-of-kin.
4.2. Conclusion
Existential vulnerability in the experiences of nursing home
doctors working in EOL care is on one hand encountered as a
burden. This is shown in feelings of powerlessness and guilt facing
prognostic and palliative challenges, the difficult balance of
treatment compromises with next-of-kin with professional
conduct, and the occasional need for protective disengagement
from difficult situations. Powerlessness may be enhanced by the
doctors’ own need for control. The shared human anxiety for death,
the stigma of death, and doctors’ sense of responsibility contribute
to vulnerability. On the other hand, existential vulnerability is also
experienced as a resource in communication and professional
coping, by allowing for meaningful experiences.
4.3. Practice implications
Existential vulnerability plays an important role in understand-
ing EOL care communication and in furthering professional self-
care and reflection. Professional conduct in EOL care is not
straightforward but needs to take into consideration both the
doctor's vulnerability as well as that of the patient and next-of-kin.
EOL care training for nursing home doctors may benefit from
including self-reflective practice, and in particular address
treatment compromises and professional conduct in the EOL
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A) SELECTION BIAS 
(Q1) Are the individuals selected to participate in the study likely to be
1 Very likely 
2 Somewhat likely 
3 Not likely 
4 Can’t tell 
(Q2) What percentage of selected individuals agreed to participate? 
1 80 - 100% agreement 
2 60 – 79% agreement 
3 less than 60% agreement 
4 Not applicable 




B) STUDY DESIGN 
Indicate the study design:
1 Randomized controlled trial 
2 Controlled clinical trial 
3 Cohort analytic (two group pre + post) 
4 Case-control 
5 Cohort (one group pre + post (before and after)) 
6 Interrupted time series 
7 Other specify ____________________________ 
8 Can’t tell 
Was the study described as randomized? If NO, go to Component C. 
No Yes 
If Yes, was the method of randomization described? (See dictionary) 
No Yes 






(Q1) Were there important differences between groups prior to the intervention? 
1 Yes 
2 No 
3 Can’t tell 
The following are examples of confounders: 
1 Race 
2 Sex 
3 Marital status/family 
4 Age 
5 SES (income or class) 
6 Education 
7 Health status 
8 Pre-intervention score on outcome measure 
(Q2) If yes, indicate the percentage of relevant confounders that were controlled 
(either in the design (e.g. stratification, matching) or analysis)?
1 80 – 100% (most) 
2 60 – 79% (some) 
3 Less than 60% (few or none) 





(Q1) Was (were) the outcome assessor(s) aware of the intervention 
1 Yes 
2 No 
3 Can’t tell 
(Q2) Were the study participants aware of the research question? 
1 Yes 
2 No 




E) DATA COLLECTION METHODS 
(Q1) Were data collection tools shown to be valid? 
1 Yes 
2 No 
3 Can’t tell 
(Q2) Were data collection tools shown to be reliable? 
1 Yes 
2 No 




F) WITHDRAWALS AND DROP-OUTS 
(Q1) Were withdrawals and drop-outs reported in terms of numbers and/or 
reasons per group? 
1 Yes 
2 No 
3 Can’t tell 
4 Not Applicable (i.e. one time surveys or interviews) 
(Q2) Indicate the percentage of participants completing the study.
 (If it differs by groups, record the lowest). 
1 80 -100% 
             2  60-79%
3 less than 60% 
4 Can’t tell 




G) INTERVENTION INTEGRITY 
(Q1) What percentage of participants received the allocated intervention 
or exposure of interest? 
1 80 -100% 
2 60-79% 
3 less than 60% 
4 Can’t tell 
(Q2) Was the consistency of the intervention measured? 
H) ANALYSES 
(Q1) Indicate the unit of allocation community  organization/institution practice/office individua
(Q2) Indicate the unit of analysis  (community  organization/institution practice/office individual)
(Q3) Is it likely that subjects received an unintended intervention that may influence the results
Yes No Can’t tell 
Yes No Can’t tell 
(Q3) Are the statistical methods appropriate for the study design? 
1 Yes 
2 No 
3 Can’t tell 
(Q4) Is the analysis performed by intervention allocation status  rather than the 
actual intervention received? 
1 Yes 
2 No 
3 Can’t tell 
GLOBAL RATING COMPONENT RATINGS 
GLOBAL RATING FOR THIS PAPER: 
1 = STRONG 
2 = MODERATE 
3 = WEAK 
With both reviewers discussing the ratings: 
(no WEAK ratings) (one WEAK rating) (two or more WEAK ratings) 
Is there a discrepancy between the two reviewers with respect to the component (A-F) ratings? No Ye
If yes, indicate the reason for the discrepancy 
1 Oversight 
2 Differences in interpretation of criteria 
3 Differences in interpretation of study 
Final decision of both reviewers : 
F) WITHDRAWALS AND DROPOUTS 
A) SELECTION BIAS  
B) STUDY DESIGN 
C) CONFOUNDERS 
D) BLINDING 
E) DATA COLLECTION METHOD 
SYSTEMATIC LITERATURE REVIEW: Search strategy  
 
Database: Embase (Ovid) 
Final search date: 21. December 2016 
 
1     death/ or dying/ (366263) 
2     terminally ill patient/ or hospice patient/ (8793) 
3     terminal care/ or hospice care/ (36872) 
4     palliative therapy/ or cancer palliative therapy/ (92150) 
5     (dying or die* or death).ti,kw. (396362) 
6     ((terminal or palliati*) adj1 care).ti,kw. (21516) 
7     "terminally ill".ti,kw. (2158) 
8     "terminal illness".ti,kw. (583) 
9     (palliati* adj1 stage*).ti,ab. (600) 
10     ("end of life" adj2 (stage or stages)).ti,ab. (113) 
11     or/1-10 (819616) 
12     "end of life".ti,ab. (21783) 
13     ((last or final) adj1 (hour* or day* or minute* or stage* or week* or month*)).ti,ab. (26216) 
14     ((dying or terminal) adj1 phase*).ti,ab. (2747) 
15     ((dying or terminal or end) adj1 stage*).ti,ab. (79293) 
16     (dying adj2 (actively or begin* or begun)).ti,ab. (98) 
17     (death adj2 (imminent* or impending or near or throes)).ti,ab. (2163) 
18     ((dying or death) adj2 (patient* or person* or people)).ti,ab. (32402) 
19     (Body adj2 (shut down or shutting down or deteriorat*)).ti,ab. (165) 
20     (deathbed or death-bed).ti,ab. (132) 
21     or/12-20 (158358) 
22     11 and 21 (47067) 
23     drug therapy/ or diuretic therapy/ or drug combination/ (662242) 
24     prescription/ (161366) 
25     exp anxiolytic agent/ (182812) 
26     exp neuroleptic agent/ (250013) 
27     exp benzodiazepine derivative/ (169759) 
28     exp antiemetic agent/ (172497) 
29     exp cholinergic receptor blocking agent/ (168289) 
30     exp diuretic agent/ (333178) 
31     (morphin* or opioid*).ti,ab,kw. (132265) 
32     (anti-anxiety agent* or Midazolam or anxiolytic* or diazepam or oxazepam or lorazepam or 
benzodiazepine*).ti,ab,kw. (88944) 
33     (antiemetic* or antipsychotic* or haldol or risperidone).ti,ab,kw. (63970) 
34     (anticholinergic* or anti-cholinergic* or glycopyrronium or scopolamine or hyoscine).ti,ab,kw. 
(25128) 
35     (diuretic* or furosemide).ti,ab,kw. (58694) 
36     or/23-35 (1717194) 
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